Compounds and therapeutic uses thereof

ABSTRACT

The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, neurodegenerative diseases including Alzheimer&#39;s disease, amyotrophic lateral sclerosis, and frontotemporal dementia, viral infection including SARS-CoV-2, and other complications associated with the foregoing diseases and disorders.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent Application No. 62/854,181 entitled “COMPOUNDS AND THERAPEUTIC USES THEREOF,” which was filed on May 29, 2019, which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates generally to the field of medicinal chemistry. Specifically, the present invention provides compounds and therapeutic uses thereof.

BACKGROUND OF THE INVENTION

PIKfyve is an endosomal lipid kinase targeted to the cytoplasmic leaflet of endosomes via protein-lipid interactions between its FYVE domain and phosphatidylinositol-3-phosphate (PI3P) within the endosomal membrane. At endosomes, PIKfyve phosphorylates PI3P to generate PI(3,5) P2, which in turn serves to control endolysosomal membrane traffic.

Lipid kinases regulate a wide variety of cellular functions, including cell growth and proliferation. Thus, lipid kinases are potential cancer therapeutic targets. In fact, there is currently a PIKfyve inhibitor being clinically investigated for the treatment of B-cell non-Hodgkin's lymphoma. There is a need for additional and alternative cancer therapeutics.

Interleukin (IL)12 and IL23 play important roles in the development of experimental autoimmune disease models and numerous afflictions affecting humans. There is a clear relationship between IL12, IL23 and the generation of pathogenic T helper cells capable of orchestrating tissue inflammation. It has been shown that IL12p40e, a common subunit shared by IL12 and IL23, is critical to pathologies associated with psoriasis, inflammatory bowel disease (IBD) and tumor growth. PIKfyve is involved in IL12/23p40 expression. There is a need for therapeutics that modulate production of IL12/IL23.

PIKfyve may impact lysosomal storage disorders. Lysosomes are organelles central to degradation and recycling processes in animal cells. Lysosomal storage disorders (LSDs) are inherited disorders that are thought to be caused by a deficiency of specific enzymes that are normally required for the breakdown of cellular metabolite substrates. If a specific lysosomal enzyme is not present in sufficient quantities, the normal breakdown of the substrate is incomplete or blocked. The cell is then unable to breakdown the material and it accumulates in the lysosomes of the cell. This accumulation disrupts the cell's normal functioning and gives rise to the clinical manifestations of LSDs.

Lysosomal storage disorders include diseases such as cholesteryl ester storage disease, gangliosidosis, Neimann-Pick disease, and MPS disorders. LSDs tend to be progressive, with the rate of progression, the severity of symptoms, and the organ systems affected varying between disorders and even within each disorder type. LSDs affect different body organs or systems including the skeleton and joints, eyes, heart, lungs, kidneys, skin, and frequently the central nervous system. There is a need for lysosomal storage disorder treatments.

Ebola virus (EBOV) is a member of the Filoviridae virus family along with Marburg virus (MARV). They are commonly known as filoviruses. PIKfyve inhibitors may be effective at inhibiting infection by filoviruses.

Consequently, there is a clear need for compounds that inhibit PIKfyve.

BRIEF SUMMARY OF THE INVENTION

The present invention provides chemical compounds that inhibit the activity of PIKfyve. These compounds can be used in the treatment of cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders.

Specifically, the present invention provides compounds of Formula I

and pharmaceutically acceptable salts and solvates thereof; wherein R, R1, R2, R3, L, W and ring A are as defined herein below.

The present invention further provides compounds of Formula II

and pharmaceutically acceptable salts and solvates thereof; wherein R, R1, R2, R3, L, W and ring A are as defined herein below.

and pharmaceutically acceptable salts and solvates thereof; wherein R, R1, R2, R3, L, X, X1, Y and ring A are as defined herein below.

The present invention further provides compounds of Formula Va

and pharmaceutically acceptable salts and solvates thereof; wherein R, R1, R2, R3, V, Ring A, Ring B, and Ring D are as defined herein below.

The present invention further provides compounds of Formula IVb

and pharmaceutically acceptable salts and solvates thereof; wherein R, R1, R3, W, L, Ring A, and Ring B are as defined herein below.

The present invention further provides compounds of Formula IVc

and pharmaceutically acceptable salts and solvates thereof; wherein R1, R3, L, M, and Ring A and Ring B are as defined herein below.

The compounds of the present invention include the compounds of the Formula I and Formula II, Formula II, Formula IVa, Formula IVb, and Formula IVc as illustrated herein and the compounds exemplified herein, as well as their geometric isomers, enantiomers, diastereomers, or racemates thereof. The compounds of the present invention also include pharmaceutically acceptable salts, prodrugs and solvates of all such compounds.

As noted above, the present invention provides chemical compounds that selectively inhibit the activity of PIKfyve, and therefore can be used in the treatment of cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders. Thus, in a related aspect, the present invention also provides methods for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders, by administering to a patient in need of such treatment a therapeutically effective amount of a compound of the present invention.

Also provided is the use of the compound of the present invention for the manufacture of a medicament useful for therapy, particularly for the treatment of cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders. In addition, the present invention also provides a pharmaceutical composition having a compound of the present invention and one or more pharmaceutically acceptable excipients. Further, methods for the treatment of cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders, by administering to a patient in need of such treatment, a pharmaceutical composition of the invention, are also encompassed.

In addition, the present invention further provides methods for treating or delaying the onset of the symptoms associated with cancer, systemic or chronic inflammation, rheumatoid arthritis, type 2 diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders. These methods comprise administering an effective amount of a compound of the present invention, preferably in the form of a pharmaceutical composition or medicament, to an individual having, or at risk of having, cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, and frontotemporal dementia, viral infection including SARS-CoV-2, and other complications associated with the foregoing diseases and disorders.

The compounds of the present invention can be used in combination therapies. Thus, combination therapy methods are also provided for treating or delaying the onset of the symptoms associated with cancer, systemic or chronic inflammation, rheumatoid arthritis, type 2 diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders. Such methods comprise administering to a patient in need thereof a compound of the present invention and, together or separately, at least one other agent for the treatment of cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders.

For the convenience of combination therapy, the compound of the present invention can be administered together in the same formulation with another agent for the treatment of cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders. Thus, the present invention also provides a pharmaceutical composition or medicament for combination therapy, comprising an effective amount of a first compound according to the present invention, and an effective amount of at least one other agent for the treatment of cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders, which is different from the first compound.

The foregoing and other advantages and features of the invention, and the manner in which they are accomplished, will become more readily apparent upon consideration of the following detailed description of the invention taken in conjunction with the accompanying examples, which illustrate preferred and exemplary embodiments.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent to one of skill in the art from the following detailed description, and from the claims.

DETAILED DESCRIPTION OF THE INVENTION 1. Definitions

As used herein, the term “alkyl” as employed herein by itself or as part of another group refers to a saturated aliphatic hydrocarbon straight chain or branched chain group having, unless otherwise specified, 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; e.g., “1 to 20 carbon atoms” means that the alkyl group may consist of 1, 2 or 3 carbon atoms, or up to 20 carbon atoms). An alkyl group may be in unsubstituted form or substituted form with one or more substituents (generally one to three substituents except in the case of halogen substituents, e.g., perchloro), such as halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups. For example, a C₁₋₆ alkyl group refers to a straight or branched aliphatic group containing 1 to 6 carbon atoms (e.g., include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, 3-pentyl, and hexyl), which may be optionally substituted.

The term “alkylene” as used herein means a saturated aliphatic hydrocarbon straight chain or branched chain group having 1 to 20 carbon atoms having two connecting points. For example, “ethylene” represents the group —CH₂—CH₂—. Alkylene groups may also be in unsubstituted form or substituted form with one or more substituents), such as halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups.

The term “alkenyl” as employed herein by itself or as part of another group means a straight or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, including at least one double bond between two of the carbon atoms in the chain. The alkenyl group may be in unsubstituted form or substituted form with one or more substituents (generally one to three substituents except in the case of halogen substituents, e.g., perchloro or perfluoroalkyls), such as halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups. For example, a C₁₋₆ alkenyl group refers to a straight or branched chain radical containing 1 to 6 carbon atoms and having at least one double bond between two of the carbon atoms in the chain (e.g., ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl and 2-butenyl, which may be optionally substituted).

The term “alkenylene” as used herein means an alkenyl group having two connecting points. For example, “ethenylene” represents the group —CH═CH—. Alkenylene groups may also be in unsubstituted form or substituted form with one or more substituents, such as halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups.

The term “alkynyl” as used herein by itself or as part of another group means a straight or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, wherein there is at least one triple bond between two of the carbon atoms in the chain. The alkynyl group may be in unsubstituted form or substituted form with one or more substituents (generally one to three substituents except in the case of halogen substituents, e.g., perchloro or perfluoroalkyls), such as halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups. For example, a C₁₋₆ alkynyl group refers to a straight or branched chain radical containing 1 to 6 carbon atoms and having at least one triple bond between two of the carbon atoms in the chain (e.g., ethynyl, 1-propynyl, 1-methyl-2-propynyl, 2-propynyl, 1-butynyl and 2-butynyl), which may be optionally substituted. The term “alkynylene” as used herein means an alkynyl having two connecting points. For example, “ethynylene” represents the group —C≡C—. Alkynylene groups may also be in unsubstituted form or substituted form with one or more substituents.

The term “carbocycle” as used herein by itself or as part of another group means cycloalkyl and non-aromatic partially saturated carbocyclic groups such as cycloalkenyl and cycloalkynyl. A carbocycle may be in unsubstituted form or substituted form with one or more substituents (such as halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups) so long as the resulting compound is sufficiently stable and suitable for the treatment method of the present invention.

The term “cycloalkyl” as used herein by itself or as part of another group refers to a fully saturated 3- to 8-membered cyclic hydrocarbon ring (i.e., a cyclic form of an unsubstituted alkyl) alone (“monocyclic cycloalkyl”) or fused to another cycloalkyl, cycloalkynyl, cycloalkenyl, heterocycle, aryl or heteroaryl ring (i.e., sharing an adjacent pair of carbon atoms with such other rings) (“polycyclic cycloalkyl”). Thus, a cycloalkyl may exist as a monocyclic ring, bicyclic ring, or a spiral ring. When a cycloalkyl is referred to as a C_(x) cycloalkyl, this means a cycloalkyl in which the fully saturated cyclic hydrocarbon ring (which may or may not be fused to another ring) has x number of carbon atoms. When a cycloalkyl is recited as a substituent on a chemical entity, it is intended that the cycloalkyl moiety is attached to the entity through a carbon atom within the fully saturated cyclic hydrocarbon ring of the cycloalkyl. In contrast, a substituent on a cycloalkyl can be attached to any carbon atom of the cycloalkyl. A cycloalkyl group may be unsubstituted or substituted with one or more substitutents (such as halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups) so long as the resulting compound is sufficiently stable and suitable for the treatment method of the present invention. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

The term “cycloalkenyl” as used herein by itself or as part of another group refers to a non-aromatic partially saturated 3- to 8-membered cyclic hydrocarbon ring having a double bond therein (i.e., a cyclic form of an unsubstituted alkenyl) alone (“monocyclic cycloalkenyl”) or fused to another cycloalkyl, cycloalkynyl, cycloalkenyl, heterocycle, aryl or heteroaryl ring (i.e., sharing an adjacent pair of carbon atoms with such other rings) (“polycyclic cycloalkenyl”). Thus, a cycloalkenyl may exist as a monocyclic ring, bicyclic ring, polycyclic or a spiral ring. When a cycloalkenyl is referred to as a C_(x) cycloalkenyl, this means a cycloalkenyl in which the non-aromatic partially saturated cyclic hydrocarbon ring (which may or may not be fused to another ring) has x number of carbon atoms. When a cycloalkenyl is recited as a substituent on a chemical entity, it is intended that the cycloalkenyl moiety is attached to the entity through a carbon atom within the non-aromatic partially saturated ring (having a double bond therein) of the cycloalkenyl. In contrast, a substituent on a cycloalkenyl can be attached to any carbon atom of the cycloalkenyl. A cycloalkenyl group may be in unsubstituted form or substituted form with one or more substitutents, such as halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups. Examples of cycloalkenyl groups include cyclopentenyl, cycloheptenyl and cyclooctenyl.

Exemplary carbocyclic groups include, but not limited to

The term “heterocycle” (or “heterocyclyl” or “heterocyclic”) as used herein by itself or as part of another group means a saturated or partially saturated 3-7 membered non-aromatic cyclic ring formed with carbon atoms and from one to four heteroatoms independently selected from the group consisting of O, N, and S, wherein the nitrogen and sulfur heteroatoms can be optionally oxidized, and the nitrogen can be optionally quaternized (“monocyclic heterocycle”). The term “heterocycle” also encompasses a group having the non-aromatic heteroatom-containing cyclic ring above fused to another monocyclic cycloalkyl, cycloalkynyl, cycloalkenyl, heterocycle, aryl or heteroaryl ring (i.e., sharing an adjacent pair of carbon atoms with such other rings) (“polycyclic heterocylce”). Thus, a heterocycle may exist as a monocyclic ring, bicyclic ring, polycyclic or a spiral ring. When a heterocycle is recited as a substituent on a chemical entity, it is intended that the heterocycle moiety is attached to the entity through an atom within the saturated or partially saturated ring of the heterocycle. In contrast, a substituent on a heterocycle can be attached to any suitable atom of the heterocycle. In a “saturated heterocycle” the non-aromatic heteroatom-containing cyclic ring described above is fully saturated, whereas a “partially saturated heterocyle” contains one or more double or triple bonds within the non-aromatic heteroatom-containing cyclic ring regardless of the other ring it is fused to. A heterocycle may be in unsubstituted form or substituted form with one or more substituents (such as halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups) so long as the resulting compound is sufficiently stable and suitable for the treatment method of the present invention.

Some examples of saturated or partially saturated heterocyclic groups include oxetanyl, azitidinyl, tetrahydrofuranyl, pyranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, imidazolinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, isochromanyl, chromanyl, pyrazolidinyl, pyrazolinyl, tetronoyl and tetramoyl groups.

Preferred heterocyclyl groups include:

As used herein, “aryl” by itself or as part of another group means an all-carbon aromatic ring with up to 7 carbon atoms in the ring (“monocylic aryl”). In addition to monocyclic aromatic rings, the term “aryl” also encompasses a group having the all-carbon aromatic ring above fused to another cycloalkyl, cycloalkynyl, cycloalkenyl, heterocycle, aryl or heteroaryl ring (i.e., sharing an adjacent pair of carbon atoms with such other rings) (“polycyclic aryl”). When an aryl is referred to as a C_(x) aryl, this means an aryl in which the all-carbon aromatic ring (which may or may not be fused to another ring) has x number of carbon atoms. When an aryl is recited as a substituent on a chemical entity, it is intended that the aryl moiety is attached to the entity through an atom within the all-carbon aromatic ring of the aryl. In contrast, a substituent on an aryl can be attached to any suitable atom of the aryl. Examples, without limitation, of aryl groups are phenyl, naphthalenyl and anthracenyl. An aryl may be in unsubstituted form or substituted form with one or more substituents (such as halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups) so long as the resulting compound is sufficiently stable and suitable for the treatment method of the present invention.

The term “heteroaryl” as employed herein refers to a stable aromatic ring having up to 7 ring atoms with 1, 2, 3 or 4 hetero ring atoms in the ring which are oxygen, nitrogen or sulfur or a combination thereof (“monocylic heteroaryl”). In addition to monocyclic hetero aromatic rings, the term “heteroaryl” also encompasses a group having the monocyclic hetero aromatic ring above fused to another cycloalkyl, cycloalkynyl, cycloalkenyl, heterocycle, aryl or heteroaryl ring (i.e., sharing an adjacent pair of carbon atoms with such other rings) (“polycyclic heteroaryl”). When a heteroaryl is recited as a substituent on a chemical entity, it is intended that the heteroaryl moiety is attached to the entity through an atom within the hetero aromatic ring of the heteroaryl. In contrast, a substituent on a heteroaryl can be attached to any suitable atom of the heteroaryl. A heteroaryl may be in unsubstituted form or substituted form with one or more substituents (such as halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups) so long as the resulting compound is sufficiently stable and suitable for the treatment method of the present invention.

Useful heteroaryl groups include thienyl (thiophenyl), benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl (furanyl), isobenzofuranyl, chromenyl, xanthenyl, phenoxanthinyl, pyrrolyl, including without limitation 2H-pyrrolyl, imidazolyl, pyrazolyl, pyridyl (pyridinyl), including without limitation 2-pyridyl, 3-pyridyl, and 4-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalzinyl, naphthyridinyl, quinozalinyl, cinnolinyl, pteridinyl, carbazolyl, β-carbolinyl, phenanthridinyl, acrindinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, thaizolyl, isothiazolyl, phenothiazinyl, oxazolyl, isoxazolyl, furazanyl, phenoxazinyl, 1,4-dihydroquinoxaline-2,3-dione, 7-aminoisocoumarin, pyrido[1,2-a]pyrimidin-4-one, pyrazolo[1,5-a]pyrimidinyl, including without limitation pyrazolo[1,5-a]pyrimidin-3-yl, 1,2-benzoisoxazol-3-yl, benzimidazolyl, 2-oxindolyl and 2-oxobenzimidazoly, oxadiazolyl, and thiadiazolyl. Where the heteroaryl group contains a nitrogen atom in a ring, such nitrogen atom may be in the form of an N-oxide, e.g., a pyridyl N-oxide, pyrazinyl N-oxide and pyrimidinyl N-oxide.

As used herein, the term “halo” refers to chloro, fluoro, bromo, or iodo substitutents.

As used herein, the term “hydro” refers to a bound hydrogen atom (—H group).

As used herein, the term “hydroxyl” refers to an —OH group.

As used herein, the term “alkoxy” refers to an —(C₁₋₁₂ alkyl). Lower alkoxy refers to —O-(lower alkyl) groups.

As used herein, the term “alkynyloxy” refers to an —O—(C₁₋₁₂ alkynyl).

As used herein, the term “cycloalkyloxy” refers to an —O-cycloakyl group.

As used herein, the term “heterocycloxy” refers to an —O-heterocycle group.

As used herein, the term “aryloxy” refers to an —O-aryl group.

The term “heteroaryloxy” refers to an —O-heteroaryl group.

The terms “arylalkoxy” and “heteroarylalkoxy” are used herein to mean an alkoxy group substituted with an aryl group and a heteroaryl group, respectively.

As used herein, the term “mercapto” group refers to an —SH group.

The term “alkylthio” group refers to an —S-alkyl group.

The term “arylthio” group refers to an —S-aryl group.

The term “arylalkyl” is used herein to mean an above-defined alkyl group substituted by an aryl group defined above. Examples of arylalkyl groups include benzyl, phenethyl and naphthylmethyl, etc. An arylalkyl group may be unsubstituted or substituted with one or more substituents so long as the resulting compound is sufficiently stable and suitable for the treatment method of the present invention.

The term “heteroarylalkyl” is used herein to mean an alkyl group defined above substituted by any heteroaryl groups. A heteroarylalkyl may be unsubstituted or substituted with one or more substituents so long as the resulting compound is sufficiently stable and suitable for the treatment method of the present invention.

The term “heteroarylalkenyl” is used herein to mean any of the above-defined alkenyl groups substituted by any of the above-defined heteroaryl groups.

The term “arylalkynyl” is used herein to mean any of the above-defined alkynyl groups substituted by any of the above-defined aryl groups.

The term “heteroarylalkenyl” is used herein to mean any of the above-defined alkenyl groups substituted by any of the above-defined heteroaryl groups.

The term “aryloxy” is used herein to mean aryl-O— wherein aryl is as defined above. Useful aryloxy groups include phenoxy and 4-methylphenoxy.

The term “heteroaryloxy” is used herein to mean heteroaryl-O— wherein heteroaryl is as defined above.

The term “arylalkoxy” is used herein to mean an alkoxy group substituted by an aryl group as defined above. Useful arylalkoxy groups include benzyloxy and phenethyloxy.

“Heteroarylalkoxy” is used herein to mean any of the above-defined alkoxy groups substituted by any of the above-defined heteroaryl groups.

“Haloalkyl” means an alkyl group that is substituted with one or more fluorine, chlorine, bromine or iodine atoms, e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, chloromethyl, chlorofluoromethyl and trichloromethyl groups.

As used herein, the term “carbonyl” group refers to a —C(═O)R″ group, where R″ is selected from the group consisting of hydro, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heterocyclic (bonded through a ring carbon), as defined herein.

As used herein, the term “aldehyde” group refers to a carbonyl group where R″ is hydro.

As used herein, the term “cycloketone” refers to a cycloalkyl group in which one of the carbon atoms which form the ring has a “═O” bonded to it; i.e., one of the ring carbon atoms is a —C(═O)— group

As used herein, the term “thiocarbonyl” group refers to a —C(═S)R″ group, with R″ as defined herein.

“Alkanoyl” refers to an alkyl-C(═O)— group.

The term “acetyl” group refers to a —C(═O)CH₃ group.

“Alkylthiocarbonyl” refers to an alkyl-C(═S)— group.

The term “cycloketone” refers to a carbocycle or heterocycle group in which one of the carbon atoms which form the ring has an oxygen double-bonded to it—i.e., one of the ring carbon atoms is a —C(═O)— group.

The term “O-carboxy” group refers to an R″C(═O)O— group, where R″ is as defined herein.

The term “C-carboxy” group refers to a —C(═O)OR″ group where R″ is as defined herein.

As used herein, the term “carboxylic acid” refers to a C-carboxy group in which R″ is hydro. In other words, the term “carboxylic acid” refers to —COOH.

As used herein, the term “ester” is a C-carboxy group, as defined herein, wherein R″ defined above except that it is not hydro (e.g., methyl, ethyl, lower alkyl).

As used herein, the term “C-carboxy salt” refers to a —C(═O)O⁻M⁺ group wherein M⁺ is selected from the group consisting of lithium, sodium, magnesium, calcium, potassium, barium, iron, zinc and quaternary ammonium.

The term “carboxyalkyl” refers to —C₁₋₆ alkylene-C(═O)OR″ (that is, a C₁₋₆ alkyl group connected to the main structure wherein the alkyl group is substituted with —C(═O)OR″ with R″ being defined herein). Examples of carboxyalkyl include, but are not limited to, —CH₂COOH, —(CH₂)₂COOH, —(CH₂)₃COOH, —(CH₂)₄COOH, and —(CH₂)₅COOH.

“Carboxyalkenyl” refers to -alkenylene-C(═O)OR″ with R″ being defined herein.

The term “carboxyalkyl salt” refers to a —(CH₂)_(r)C(═O)O⁻M⁺ wherein M⁺ is selected from the group consisting of lithium, sodium, potassium, calcium, magnesium, barium, iron, zinc and quaternary ammonium.

The term “carboxyalkoxy” refers to —O—(CH₂)_(r)C(═O)OR″ wherein r is 1-6, and R″ is as defined herein.

“C_(x) carboxyalkanoyl” means a carbonyl group (—(O═)C—) attached to an alkyl or cycloalkylalkyl group that is substituted with a carboxylic acid or carboxyalkyl group, wherein the total number of carbon atoms is x (an integer of 2 or greater).

“C_(x) carboxyalkenoyl” means a carbonyl group (—(O═)C—) attached to an alkenyl or alkyl or cycloalkylalkyl group that is substituted with a carboxylic acid or carboxyalkyl or carboxyalkenyl group, wherein at least one double bond (—CH═CH—) is present and wherein the total number of carbon atoms is x (an integer of 2 or greater).

“Carboxyalkoxyalkanoyl” refers to R″OC(═O)—C₁₋₆ alkylene-O—C₁₋₆ alkylene-C(═O)—, where R″ is as defined herein.

“Amino” refers to an —NR^(x)R^(y) group, with R^(x) and R^(y) as defined herein.

“Alkylamino” means an amino group with a substituent being a C₁₋₆ alkyl.

“Aminoalkyl” means an alkyl group connected to the main structure of a molecule where the alkyl group has a substituent being amino.

“Quaternary ammonium” refers to a —⁺N(R^(x))(R^(y))(R^(z)) group wherein R^(x), R^(y), and R^(z) are as defined herein.

The term “nitro” refers to a —NO₂ group.

The term “O-carbamyl” refers to a —OC(═O)N(R^(x))(R^(y)) group with R^(x) and R^(y) as defined herein.

The term “N-carbamyl” refers to a R^(y) OC(═O)N(R^(x))— group, with R^(x) and R^(y) as defined herein.

The term “O-thiocarbamyl” refers to a —OC(═S)N(R^(x))(R^(y)) group with R^(x) and R^(y) as defined herein.

The term “N-thiocarbamyl” refers to a R^(x)OC(═S)NR^(y))— group, with R^(x) and R^(y) as defined herein.

“C-amido” refers to a —C(═O)N(R^(x))(R^(y)) group with R^(x) and R^(y) as defined herein.

“N-amido” refers to a R^(x)C(═O)N(R^(y))— group with R^(x) and R^(y) as defined herein.

“Aminothiocarbonyl” refers to a —C(═S)N(R^(x))(R^(y)) group with R^(x) and R^(y) as defined herein.

“Hydroxyaminocarbonyl” means a —C(═O)N(R^(x))(OH) group with R^(x) as defined herein.

“Alkoxyaminocarbonyl” means a —C(═O)N(R^(x))(alkoxy) group with R^(x) as defined herein.

The terms “cyano” and “cyanyl” refer to a —C≡N group.

The term “nitrile” group, as used herein, refers to a —C≡N substituent.

The term “cyanato” refers to a —CNO group.

The term “isocyanato” refers to a —NCO group.

The term “thiocyanato” refers to a —CNS group. The term “isothiocyanato” refers to a —NCS group.

The term “sulfinyl” refers to a —S(═O)R″ group, where R″ is as defined herein.

The term “sulfonyl” refers to a —S(═O)₂R″ group, where R″ is as defined herein.

The term “sulfonamide” refers to a —(R″)N—S(═O)₂R″ group, with R″ and R^(x) as defined herein.

“Aminosulfonyl” means (R^(x))(R^(y))N—S(═O)₂— with R^(x) and R^(y) as defined herein.

“Aminosulfonyloxy” means a (R_(x))(R^(y))N—S(═O)₂—O— group with R^(x) and R^(y) as defined herein.

“Sulfonamidecarbonyl” means R″—S(═O)₂—N(R^(x))—(═O)— with R″ and R^(x) as defined herein.

“Alkanoylaminosulfonyl” refers to an alkyl-C(═O)—N(R′)—S(═O)₂— group with R^(x) as defined herein.

The term “trihalomethylsulfonyl” refers to a X₃CS(═O)₂— group with X being halo.

The term “trihalomethylsulfonamide” refers to a X₃CS(═O)₂N(R^(x))— group with X being halo and R^(x) as defined herein.

R″ is selected from the group consisting of hydro, alkyl, cycloalkyl, aryl, heteroaryl and heterocycle, each being optionally substituted.

R^(x), R^(y), and R^(z) are independently selected from the group consisting of hydro and optionally substituted alkyl.

The term “methylenedioxy” refers to a —OCH2O— group wherein the oxygen atoms are bonded to adjacent ring carbon atoms.

The term “ethylenedioxy” refers to a —OCH2CH2O— group wherein the oxygen atoms are bonded to adjacent ring carbon atoms.

The term “bioisostere,” as used herein, generally refers to compounds or moieties that have chemical and physical properties producing broadly similar biological properties. Examples of carboxylic acid bioisosteres include, but are not limited to, carboxyalkyl, carboxylic acid ester, tetrazole, oxadiazole, isoxazole, hydroxythiadiazole, thiazolidinedione, oxazolidinedione, sulfonamide, aminosulfonyl, sulfonamidecarbonyl, C-amido, sulfonylcarboxamide, phosphonic acid, phosphonamide, phosphinic acid, sulfonic acid, alkanoylaminosufonyl, mercaptoazole, trifluoromethylcarbonyl, and cyanamide.

Unless specifically stated otherwise or indicated by a bond symbol (dash, double dash, or triple dash), the connecting point to a recited group will be on the right-most stated group. Thus, for example, a hydroxyalkyl group is connected to the main structure through the alkyl and the hydroxyl is a substituent on the alkyl.

2. Therapeutic Compounds

The present invention provides chemical compounds that selectively inhibit the activity of PIKfyve. These compounds can be used in the treatment of cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders.

Specifically, the present invention provides compounds of Formula I

and pharmaceutically acceptable salts and solvates thereof; wherein R, R1, R2, R3, L, W and ring A are as defined herein below. n=1 or 2.

R represents a hydrogen atom, aryl, heteroaryl, alkyl, heterocyclyl, carbocyclo, carbocycloalkyl, carbocycloalkenyl, carbocycloalkynyl, heterocyclylalkyl, heterocycloalkenyl, heterocycloalkynyl, arylalkyl, arylalkenyl, arylalkynyl heteroarylalkyl, heteroarylalkenyl, or heteroarylalkynyl, any of which may have one more or substituents.

W represents a single bond, CH2, —(CH2)n-, S(O), S(O2), NRa, C(O), C(O)NRa, NRaC(O), S(O2)NRa, NRaS(O2), CRa═CRb, C═NRa, or NRa═CRb, —O(CH2)n-, NRa(CH2)n-, where n=0 or 1-5 and Ra and Rb are the same or independently represent a hydrogen atom, aryl, heteroaryl, alkyl, heterocyclyl, carbocyclo, carbocycloalkyl, carbocycloalkenyl, carbocycloalkynyl, heterocyclylalkyl, heterocycloalkenyl, heterocycloalkynyl, arylalkyl, arylalkenyl, arylalkynyl heteroarylalkyl, heteroarylalkenyl, or heteroarylalkynyl, any of which may have one more or substituents.

R1 and R2 are the same or different, are independently represents a hydrogen atom, hydroxyl group, aryl, heteroaryl, cycloalkyl, or heterocyclyl.

R3 is a group selected from the group consisting of a hydrogen atom, an alkyl group which may have a substituent(s), an alkylsulfonyl group which may have a substituent(s), an acyl group which may have a substituent(s), an alkoxycarbonyl group which may have a substituent(s), a C-amido group which may have a substituent(s), an aliphatic ring which may have a substituent(s), an aryl group which may a substituent(s), a heteroaryl group which may have a substituent(s) or aliphatic ring with one or more heteroatom(s) and which may have a substituent(s).

L is a group selected from a hydrogen atom or a group represented by the following general formula:

where n=0, 1-3; R^(a) R^(b), R^(c), R^(d), and R^(e) each independently represent a hydrogen atom, C1-C6 alkyl group, aryl, heteroaryl, cycloalkyl, or heterocyclyl group, any of which may have one or more substituents.

Or, R3 and L together form a 4 to 6 membered heterocyclic or heteroaryl ring, optionally substituted by one or more substituents, these substituents independently representing a hydrogen atom, C1-C6 alkyl group, aryl, heteroaryl, carbocyclo, or heterocyclyl group which may have one or more substituents.

Ring A is a carbocycle, heterocycle, or heteroaryl, any of which may have a substitutent(s). The ring preferably used herein is one represented by the following formula:

where Q represents N or CH and M is O, S, S(O), S(O2), or NRd, where Rd is a hydrogen atom, a hydroxyl group, an alkyl group which may have a substitutent(s) or an acyl group.

In some embodiments, Ring A is an optionally substituted 5-6 membered saturated or partially unsaturated heterocyclic ring having one or two heteroatoms independently selected from nitrogen, oxygen or sulfur. In some embodiments, Ring A is unsubstituted morpholinyl. In some embodiments, ring A is optionally substituted tetrahydropyranyl. In certain embodiments, Ring A is selected from:

In certain embodiments, Ring A is an optionally substituted 5-10 membered saturated or partially unsaturated bridged bicyclic heterocyclic ring having at least one nitrogen, at least one oxygen, and optionally 1-2 additional heteroatoms independently selected from nitrogen, oxygen and sulfur. In certain embodiments, Ring A is a bridged, bicyclic morpholino group. In certain embodiments, Ring A is selected from:

The present invention also provides compounds of Formula II

and pharmaceutically acceptable salts and solvates thereof; wherein n=1 or 2, and R, R1, R2, R3, L, W and ring A are as defined in Formula I above.

The present invention also provides compounds of Formula III

and pharmaceutically acceptable salts and solvates thereof; wherein R, R^(a), R2, R3, L, ring A are as defined in Formula I above, wherein X, X1, and Y are independently nitrogen or carbon. In some embodiments, X, X1, and Y are all nitrogen. In some embodiments, R and R together form a 3 to 7 membered heterocyclo ring, optionally substituted by one or more substituents.

The present invention also provides compounds of Formula IVa

and pharmaceutically acceptable salts and solvates thereof; wherein R, R1, R2, R3, W and ring A are as defined in Formula I above. The group V may or may not present. If V is present, it is selected from the group consisting —O—, —S—, —CH2, —(CH2)n-, S(O), S(O2), NRa, C(O), C(O)NRa, NRaC(O), S(O2)NRa, NRaS(O2), CRa═CRb, C═NRa, or NRa═CRb, —O(CH2)n-, NRa(CH2)n-, where n=0, 1-5 and Ra and Rb are the same or independently represent a hydrogen atom, C1-C6 alkyl aryl, heteroaryl, cycloakyl, or cycloheteroalkyl group which may have one or more substituents. Ring B is aryl, heteroaryl and bicyclicheteroaryl.

For example, Ring B may be selected from the group consisting of:

Ring D is heteroaryl, aryl or heterocyclyl.

In some embodiments, ring D is

wherein Q is CR4 or N, and wherein R2 is as defined above, wherein R4 represents a hydrogen atom, hydroxyl, alkoxy, halogen (halo), hydroxy, NH2, NRa, aryl, heteroaryl, alkyl, cycloalkyl, cycloalkoxy, or heterocyclyl, any of which may have one more or substituents.

In some embodiments, D has a structure selected from

wherein R2, R3 as defined above in Formula 1; R5 represents aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, or heterocyclyl, any of which may have one more or substituents; and R6 represents a hydrogen atom, aryl, heteroaryl, alkyl, cycloalkyl, or heterocyclyl, any of which may have one more or substituents. In some embodiments R5 represents NR^(a)R^(b), R^(a) and R^(b) are independently selected from aryl, heteroaryl, alkyl, cycloalkyl, or heterocyclyl, any of which may have one more or substituents, or R^(a) and R^(b) together form a 3 to 7 membered heterocyclic ring, optionally substituted by one or more substituents.

In some embodiment, if V is not present, ring B is directly attached to ring D. The ring D is defined as above. R2 and R3 are independently selected from H, hydroxy, halogen (F, Cl, Br or I), —CN, —OR′, —S(O) R′, —S(O)2R′, —SO2N R′R″, —N R′R″, —(CO)YR″, —Y(CO) R″, —NR′ (CO)Y R′, —N R′C(═S)Y R″, —OC(═S)Y R″, —C(═S)YR″, R′ is independently selected from H or C1-C4 alkyl. R″ is independently selected from hydrogen or five to six membered heterocycles described as defined in ring D. Y is independently a bond, —N—, or —NH—

In some embodiment, R2 is H, hydroxyl, halogen (F, Cl, Br or I), C1-C4 alkyl, C1-C4 branched alkyl, cycloalkyl, cyclohetroalkyl and R3 is —NHR′″, R′″ is selected, but not limited to the following groups

In some embodiment, R2 is H, hydroxyl, halogen (F, Cl, Br or I), C1-C4 alkyl, C1-C4 branched alkyl, cycloalkyl, cyclohetroalkyl and R3 is —NHR″″, R″″ is selected, but not limited to the following groups.

R′″ is defined as above.

In some embodiment R2 is H, hydroxyl, halogen (F, Cl, Br or I), C1-C4 alkyl, C1-C4 branched alkyl, cycloalkyl, cyclohetroalkyl and R3 is —C(═O) R′″″, R′″″ is selected, but not limited to the following groups

wherein R′″ is defined as above.

The present invention also provides compounds of Formula IVb

Ring A and W are as defined in Formula I above

Ring B are as defined below

W is as defined in Formula IVa above.

L is defined below

R, R1, R3, R^(a), R^(b), R^(c), R^(d) and R^(e) are as defined in Formula I above.

X=—O—, —S—

The present invention also provides compounds of Formula IVc

Ring A as defined in Formula I above

Ring B are as defined in Formula IVa

L is defined above

R3 is defined in formula I

M represents a hydrogen atom, aryl, heteroaryl, alkyl, cycloalkyl, or heterocyclyl, any of which may have one more or substituents. M may be a halo, alkoxy depending on the valence of the atom to which it is attached.

In some embodiments, M is

The pharmaceutically acceptable addition salts as mentioned herein are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of Formula I, Formula II, Formula III, Formula IVa, Formula IVb and Formula IVc are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g., hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxy-acetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free base form.

The compounds of the present invention containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g., the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g., primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline, the benzathine, N-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like. Conversely the salt form can be converted by treatment with acid into the free acid form.

The term “addition salt” also comprises the hydrates and solvent addition forms which the compounds of the present invention are able to form. Examples of such forms are, e.g., hydrates, alcoholates and the like.

The term “quaternary amine” as used hereinbefore defines the quaternary ammonium salts which the compounds of the present invention are able to form by reaction between a basic nitrogen of a compound of the present invention and an appropriate quaternizing agent, such as, for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g., methyliodide or benzyliodide. Other reactants with good leaving groups may also be used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl p-toluenesulfonates. A quaternary amine has a positively charged nitrogen. Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate and acetate. The counterion of choice can be introduced using ion exchange resins.

Pharmaceutically acceptable salts of the compounds of the present invention include all salts that are exemplified by alkaline salts with an inorganic acid and/or a salt with an organic acid that are known in the art. In addition, pharmaceutically acceptable salts include acid salts of inorganic bases, as well as acid salts of organic bases. Their hydrates, solvates, and the like are also encompassed in the present invention. In addition, N-oxide compounds are also encompassed in the present invention.

It will be appreciated that some of the compounds of the present invention and their N-oxides, addition salts, quaternary amines and stereochemically isomeric forms may contain one or more centers of chirality and exist as stereochemically isomeric forms.

The term “stereochemically isomeric forms” as used hereinbefore defines all the possible stereoisomeric forms which the compounds of the present invention, and their N-oxides, addition salts, quaternary amines or physiologically functional derivatives may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms of the compounds of the present invention and their N-oxides, salts, solvates or quaternary amines substantially free, i.e., associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers. In particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration. Compounds encompassing double bonds can have an E- or Z-stereochemistry at said double bond. Stereochemically isomeric forms of the compounds of the present invention are fully intended to be embraced within the scope of this invention.

The N-oxide forms of the present compounds are meant to comprise the compounds of the present invention wherein one or several nitrogen atoms are oxidized to the so-called N-oxide.

Some of the compounds of the present invention may also exist in their tautomeric form. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

Whenever used hereinafter, the term “compounds of the present invention” is meant to also include their N-oxide forms, their salts, their solvates, their clathrates, their hydrates, their polymorphs, their prodrugs, their bioisosteres, their quaternary amines, their stereochemically isomeric forms, and any other of their analogs or derivatives. Further, it should be understood that the methods of the present invention include the use of all such forms, and especially those forms that possesses PIKfyve inhibitory activity, or other advantageous properties. Of special interest are those compounds of the present invention that are stereochemically pure.

In all compounds of the present invention, reference to any bound hydrogen atom can also encompass a deuterium atom bound at the same position. Substitution of hydrogen atoms with deuterium atoms is conventional in the art. See. e.g., U.S. Pat. Nos. 5,149,820 & 7,317,039, which are incorporated by reference herein in their entirety. Such deuteration sometimes results in a compound that is functionally indistinct from its hydrogenated counterpart, but occasionally results in a compound having beneficial changes in the properties relative to the non-deuterated form. For example, in certain instances, replacement of specific bound hydrogen atoms with deuterium atoms dramatically slows the catabolism of the deuterated compound, relative to the non-deuterated compound, such that the deuterated compound exhibits a significantly longer half-life in the bodies of individuals administered such compounds. This is particularly so when the catabolism of the hydrogenated compound is mediated by cytochrome P450 systems. See Kushner et al., Can. J. Physiol. Pharmacol. (1999) 77:79-88, which is incorporated by reference herein in its entirety.

3. Pharmaceutical Compositions and Formulations

In another aspect, the present invention further provides a medicament or a pharmaceutical composition having a therapeutically or prophylactically effective amount of a therapeutic compound according to the present invention (i.e., a compound of the present invention) and a pharmaceutically-acceptable excipient.

Typically, therapeutic compounds according to the present invention can be effective at an amount of from about 0.01 μg/kg to about 100 mg/kg per day based on total body weight. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at predetermined intervals of time. The suitable dosage unit for each administration can be, e.g., from about 1 μg to about 2000 mg, preferably from about 5 μg to about 1000 mg. In the case of combination therapy, a therapeutically effective amount of one or more other anticancer compounds can be administered in a separate pharmaceutical composition, or alternatively included in the pharmaceutical composition according to the present invention which contains a compound according to the present invention. The pharmacology and toxicology of many of such other anticancer compounds are known in the art. See. e.g., Physicians Desk Reference, Medical Economics, Montvale, N.J.; and The Merck Index, Merck & Co., Rahway, N.J. The therapeutically effective amounts and suitable unit dosage ranges of such compounds used in the art can be equally applicable in the present invention.

It should be understood that the dosage ranges set forth above are exemplary only and are not intended to limit the scope of this invention. The therapeutically effective amount for each active compound can vary with factors including but not limited to the activity of the compound used, stability of the active compound in the patient's body, the severity of the conditions to be alleviated, the total weight of the patient treated, the route of administration, the ease of absorption, distribution, and excretion of the active compound by the body, the age and sensitivity of the patient to be treated, and the like, as will be apparent to a skilled artisan. The amount of administration can be adjusted as the various factors change over time.

In the pharmaceutical compositions, the active agents (i.e., the compounds of the present invention) can be in any pharmaceutically acceptable salt form, as further described above.

For oral delivery, the active compounds can be incorporated into a formulation that includes pharmaceutically acceptable excipients or carriers such as binders, lubricants, disintegrating agents, and sweetening or flavoring agents, all known in the art. The formulation can be orally delivered in the form of enclosed gelatin capsules or compressed tablets. Capsules and tablets can be prepared in any conventional techniques. The capsules and tablets can also be coated with various coatings known in the art to modify the flavors, tastes, colors, and shapes of the capsules and tablets. In addition, liquid carriers such as fatty oil can also be included in capsules.

Suitable oral formulations can also be in the form of a solution, suspension, syrup, chewing gum, wafer, elixir, and the like. If desired, conventional agents for modifying flavors, tastes, colors, and shapes of the special forms can also be included.

The active compounds can also be administered parenterally in the form of solution or suspension, or in lyophilized form capable of conversion into a solution or suspension form before use. In such formulations, diluents or pharmaceutically acceptable carriers such as sterile water and physiological saline buffer can be used. Other conventional solvents, pH buffers, stabilizers, anti-bacteria agents, surfactants, and antioxidants can all be included. The parenteral formulations can be stored in any conventional containers such as vials and ampoules.

Routes of topical administration include nasal, bucal, mucosal, rectal, or vaginal applications. For topical administration, the active compounds can be formulated into lotions, creams, ointments, gels, powders, pastes, sprays, suspensions, drops and aerosols. Thus, one or more thickening agents, humectants, and stabilizing agents can be included in the formulations. A special form of topical administration is delivery by a transdermal patch. Methods for preparing transdermal patches are disclosed, e.g., in Brown, et al., Annual Review of Medicine, 39:221-229 (1988), which is incorporated herein by reference.

Subcutaneous implantation for sustained release of the active compounds may also be a suitable route of administration. This entails surgical procedures for implanting an active compound in any suitable formulation into a subcutaneous space, e.g., beneath the anterior abdominal wall. See. e.g., Wilson et al., J. Clin. Psych. 45:242-247 (1984). Hydrogels can be used as a carrier for the sustained release of the active compounds. Hydrogels are generally known in the art. They are typically made by crosslinking high molecular weight biocompatible polymers into a network, which swells in water to form a gel-like material. Preferably, hydrogels are biodegradable or biosorbable. See. e.g., Phillips et al., J. Pharmaceut. Sci., 73:1718-1720 (1984).

The active compounds can also be conjugated to a water soluble non-immunogenic non-peptidic high molecular weight polymer to form a polymer conjugate. For example, an active compound is covalently linked to polyethylene glycol to form a conjugate. Typically, such a conjugate exhibits improved solubility, stability, and reduced toxicity and immunogenicity. Thus, when administered to a patient, the active compound in the conjugate can have a longer half-life in the body, and exhibit better efficacy. See generally Burnham, Am. J. Hosp. Pharm., 15:210-218 (1994). PEGylated proteins are currently being used in protein replacement therapies and for other therapeutic uses. For example, PEGylated interferon (PEG-INTRON A®) is clinically used for treating Hepatitis B. PEGylated adenosine deaminase (ADAGEN®) is being used to treat severe combined immunodeficiency disease (SCIDS). PEGylated L-asparaginase (ONCAPSPAR®) is being used to treat acute lymphoblastic leukemia (ALL). It is preferred that the covalent linkage between the polymer and the active compound and/or the polymer itself is hydrolytically degradable under physiological conditions. Such conjugates known as “prodrugs” can readily release the active compound inside the body. Controlled release of an active compound can also be achieved by incorporating the active ingredient into microcapsules, nanocapsules, or hydrogels generally known in the art.

Liposomes can also be used as carriers for the active compounds of the present invention. Liposomes are micelles made of various lipids such as cholesterol, phospholipids, fatty acids, and derivatives thereof. Various modified lipids can also be used. Liposomes can reduce the toxicity of the active compounds, and increase their stability. Methods for preparing liposomal suspensions containing active ingredients therein are generally known in the art. See. e.g., U.S. Pat. No. 4,522,811; Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976).

The active compounds of the present invention can also be administered in combination with another active agent that synergistically treats or prevents the same symptoms or is effective for another disease or symptom in the patient being treated, so long as the other active agent does not interfere with, or adversely affect, the effects of the active compounds of the present invention. Such other active agents include but are not limited to agents for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, IL12/IL23 excess production diseases, filoviral, lysosomal disorders, and the like.

4. Therapeutic Methods

The present invention provides therapeutic methods for treating diseases and disorders that will respond to therapy with a PIKfyve inhibitor. Consequently, the present invention provides therapeutic methods for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, IL12/IL23 excess production diseases, filoviral, lysosomal disorders and other complications associated with these diseases and disorders. These therapeutic methods involve treating a patient (either a human or another animal) in need of such treatment, with a therapeutically effective amount of a compound of the present invention, or a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention.

The present invention also comprises treating isolated cells with a therapeutically effective amount of a compound of the present invention, or a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention.

As used herein, the phrase “treating . . . with . . . a compound” means either administering a compound of the present invention, or a pharmaceutical composition comprising a compound of the present invention, directly to isolated cells or to an animal, or administering to cells or an animal another agent to cause the presence or formation of a compound of the present invention inside the cells or the animal. Preferably, the methods of the present invention comprise administering to cells in vitro or to a warm-blooded animal, particularly a mammal, and more particularly a human, a pharmaceutical composition comprising an effective amount of a compound according to the present invention causing the presence or formation of the compound of the present invention inside the cells or the animal.

As would be appreciated by the skilled artisan, a therapeutic compound of the present invention may be administered in one dose at one time, or may be divided into a number of smaller doses to be administered at predetermined intervals of time. The suitable dosage unit for each administration can be determined based on the effective daily amount and the pharmacokinetics of the compounds. In the case of combination therapy, a therapeutically effective amount of one or more other therapeutically effective compounds can be administered in a separate pharmaceutical composition, or alternatively included in the same pharmaceutical composition according to the present invention which contains a compound according to the present invention. The pharmacology and toxicology of many therapeutically effective compounds are known in the art. See. e.g., Physicians Desk Reference, Medical Economics, Montvale, N.J.; and The Merck Index, Merck & Co., Rahway, N.J. The therapeutically effective amounts and suitable unit dosage ranges of such compounds used in the art can be equally applicable in the present invention.

It should be understood that the dosage range set forth herein is exemplary only and is not intended to limit the scope of this invention. The therapeutically effective amount for each active compound of the invention can vary with factors including but not limited to the activity of the compound used, stability of the active compound in the patient's body, the severity of the conditions to be alleviated, the total weight of the patient treated, the route of administration, the ease of absorption, distribution, and excretion of the active compound by the body, the age and sensitivity of the patient to be treated, and the like, as will be apparent to a skilled artisan. The amount of administration can be adjusted as the various factors change over time.

In one set of aspects, the present invention also provides methods for combination therapy for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, and other complications associated with these diseases and disorders, by treating a patient in need thereof, with a therapeutically effective amount of a compound of the present invention together with a therapeutically effective amount of one or more other compounds that have been shown to be effective in the treatment of cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.

For the convenience of combination therapy, the compound of the present invention can be administered together in the same formulation with the one or more other compounds that have been shown to be effective in the treatment of cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders, in the same formulation or dosage form. Thus, the present invention also provides pharmaceutical compositions or medicaments for combination therapy, comprising an effective amount of a compound of the present invention, and an effective amount of at least one other compound that has been shown to be effective in the treatment of cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders.

The present invention provides methods for the treatment of cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a composition of the present invention, said composition comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, polymorph, prodrug, analog or derivative thereof. The present invention further provides the use of a composition for the preparation of a medicament useful for the treatment of cancer.

In another aspect, the invention provides a method for treating an individual having an PIKfyve inhibitor-sensitive disease or disorder chosen from inflammatory diseases, viral or bacterial infections, autoimmune disorders, stroke, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, cardiac disorders, neurological disorders, proliferative disorders, neoplasms, malignant diseases, and metabolic diseases.

In yet another aspect, the invention provides a method for treating an individual having a PIKfyve inhibitor-sensitive fibrogenetic disorder, such as, for example, scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis and pulmonary fibrosis.

As used herein, the term “pharmaceutically acceptable salt,” is a salt formed from, for example, an acid and a basic group of a composition of the invention. Illustrative salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, besylate, gentisinate, funarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, and pamoate.

a. Treating Cancer

It has been observed that loss of PIKfyve activity results in disruption of endosome and lysosome membrane trafficking. It has been observed that PIKfyve inhibition increases the nuclear abundance of TFEB and induces upregulation of numerous lysosome and autophagy-related genes. It has been predicted that increased lysosomal protein expression under conditions where endolysosomal membrane traffic is impaired may stress tumor cells and contribute to their death. See. e.g., Gayle et al., Blood, 129(13):1768-78 (2017).

In view of at least the above, it is believed that inhibition of PIKfyve activity would be effective in treating of a wide range of cancers. Consequently, the present invention provides methods of treating a wide range of cancers by administering therapeutically effective amounts of the PIKfyve-inhibiting compounds of the present invention.

As used herein, the term “cancer” has its conventional meaning in the art. Cancer includes any condition of the animal or human body characterized by abnormal cellular proliferation. The cancers to be treated comprise a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. Compounds of the present invention have been shown to be effective in a variety of standard cancer models, and are thus thought to have utility in treating a broad range of cancers. However, preferred methods of the invention involve treating cancers that have been found to respond favorably to treatment with PIKfyve inhibitors. Further, “treating cancer” should be understood as encompassing treating a patient who is at any one of the several stages of cancer, including diagnosed but as yet asymptomatic cancer.

A patient having cancer can be identified by conventional diagnostic techniques known in the art, and the identified patient can be treated with a compound of the present invention, preferably in a pharmaceutical composition having a pharmaceutically acceptable carrier.

The present invention provides therapeutic methods comprising administering to an animal (e.g., a patient, in need of such treatment) a therapeutically effective amount of one or more compounds of Formulae I, II, III, IVa, IVb and IVc as defined above, and/or a pharmaceutically acceptable salt thereof.

Specific cancers that can be treated by the methods of the invention are those cancers that respond favorably to treatment with a PIKfyve inhibitor. Such diseases include, but are not limited to, brain cancer, glioma, sarcoma, breast cancer, lung cancer, non-small-cell lung cancer, mesothelioma, appendiceal cancer, genitourinary cancers, renal cell carcinoma, prostate cancer, bladder cancer, testicular cancer, penile cancer, cervical cancer, ovarian cancer, von Hippel Lindau disease, head and neck cancer, gastrointestinal cancer, hepatocellular carcinoma, gallbladder cancer, esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, neuroendocrine tumor, thyroid tumor, pituitary tumor, adrenal tumor, hematological malignancy, leukemia, Wilms' tumor, choriocarcinoma, mycosis fungoides, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, soft-tissue sarcomaacute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, and skin cancer.

In one embodiment the cancer is a lymphoma. In one embodiment, the lymphoma is a B-cell lymphoma. In one embodiment, the B-cell lymphoma is selected from the group consisting of a Hodgkin's B-cell lymphoma and a non-Hodgkin's B-cell lymphoma. In one embodiment, the B-cell lymphoma is a non-Hodgkin's B-cell lymphoma selected from the group consisting of DLBCL, follicular lymphoma, marginal zone lymphoma (MZL) or mucosa associated lymphatic tissue lymphoma (MALT), small cell lymphocytic lymphoma (overlaps with chronic lymphocytic leukemia) and mantle cell lymphoma. In one embodiment, the B-cell lymphoma is a non-Hodgkin's B-cell lymphoma selected from the group consisting of Burkitt lymphoma, Primary mediastinal (thymic) large B-cell lymphoma, lymphoplasmacytic lymphoma, which may manifest as Waldenstrom macroglobulinemia, Nodal marginal zone B-cell lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, T-cell/histiocyte-rich large B-cell lymphoma, primary central nervous system lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type (primary cutaneous DLBCL, leg type), EBV positive diffuse large B-cell lymphoma of the elderly, diffuse large B-cell lymphoma associated with inflammation, intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, and plasmablastic lymphoma.

b. Treating IL12/IL23 Excessive Production

Interleukin (IL)12 and IL23 play important roles in the development of experimental autoimmune disease models and numerous afflictions affecting humans. There is a clear relationship between IL12, IL23 and the generation of pathogenic T helper cells capable of orchestrating tissue inflammation. It has been shown that IL12p40, a common subunit shared by IL12 and IL23, is critical to pathologies associated with psoriasis, inflammatory bowel disease (IBD) and tumor growth. PIKfyve is involved in IL12/23p40 expression.

IL12/IL23 excessive production is involved in various diseases, e.g., multiple sclerosis, systemic sclerosis, sepsis, myasthenia gravis, autoimmune neurological disease, Guillain-Barre syndrome, autoimmune uveitides, autoimmune hemolytic anemia, pernicious anemia, autoimmune thrombocytopenia, temporal arteritis, antiphospholipid syndrome, vasculitis, Wegener's granulomatosis, Behcet's disease, psoriasis, psoriatic arthritis, herpetic dermatitis, pemphigus vulgaris, vitiligo, Crohn's disease, ulcerative colitis, interstitial fibroid lung, myelofibrosis, hepatic fibrosis, myocarditis, autoimmune thyroid disease (Graves' disease, Hashimoto's disease), primary biliary cirrhosis, autoimmune hepatitis, immune-mediated diabetes mellitus, autoimmune oophoritis and orchitis, autoimmune adrenalitis, rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis, and dermatomyositis.

In view of the above, it is believed that inhibition of PIKfyve activity would be effective in treating diseases associated with over production of IL12/IL23. Consequently, the present invention provides methods of treating systemic or chronic inflammation by administering therapeutically effective amounts of the PIKfyve-inhibiting compounds of the present invention.

c. Lysosomal Storage Disorders

Lysosomes are organelles central to degradation and recycling processes in animal cells. Lysosomal storage disorders (LSDs) are inherited disorders that are thought to be caused by a deficiency of specific enzymes that are normally required for the breakdown of cellular metabolite substrates. If a specific lysosomal enzyme is not present in sufficient quantities, the normal breakdown of the substrate is incomplete or blocked. The cell is then unable to break down the material and it accumulates in the lysosomes of the cell. This accumulation disrupts the cell's normal functioning and gives rise to the clinical manifestations of LSDs.

Lysosomal storage disorders include diseases such as cholesteryl ester storage disease, gangliosidosis, Neimann-Pick disease, and MPS disorders. LSDs tend to be progressive, with the rate of progression, the severity of symptoms, and the organ systems affected varying between disorders and even within each disorder type. LSDs affect different body organs or systems including the skeleton and joints, eyes, heart, lungs, kidneys, skin, and frequently the central nervous system.

In some embodiments, the lysosomal storage disease may be selected from the group consisting of activator deficiency; aspartylglucosaminuria; GM2-gangliosidosis; GM2-gangliosidosis, AB variant; alpha-mannosidosis; beta-mannosidosis; bilateral temporooccipital polymicrogyria (BTOP); lysosomal acid lipase deficiency; lysosomal acid lipase deficiency; cystinosis; Chanarin-Dorfman syndrome; Danon disease; Dent-1; Dent disease 2; Fabry disease; Farber disease; Farber lipogranulomatosis; fucosidosis; galactosialidosis (combined neuraminidase and beta-galactosidase deficiency); Gaucher disease; GM1-gangliosidosis; globoid cell leukodystrophy; infantile free sialic acid storage disease (ISSD); Kanzaki disease; Krabbe disease; metachromatic leukodystrophy; a mucopolysaccharidoses disorder; Morquio syndrome, type A/MPS IVA; Morquio syndrome, type B/MPS IVB; MPS IX hyaluronidase deficiency; MPS VI Maroteaux-Lamy syndrome; MPS VII Sly syndrome; mucolipidosis I, sialidosis; I-cell disease; Leroy disease; mucolipidosis II; pseudo-Hurler polydystrophy/mucolipidosis type III; mucolipidosis IIIC/ML III GAMMA; mucolipidosis type IV; multiple sulfatase deficiency; Niemann-Pick disease; a neuronal ceroid lipofuscinoses, Pompe disease (glycogen storage disease type II), pycnodysostosis, Sandhoff disease/GM2 gangliosidosis; Sanfilippo syndrome Type A/MPS IIIA; Sanfilippo syndrome Type B/MPS IIIB; Sanfilippo syndrome Type C/MPS IIIC; Sanfilippo syndrome Type D/MPS IIID; Schindler disease; Salla disease; spinal muscular atrophy with progressive myoclonic epilepsy (SMAPME); myoclonic epilepsy (SMAPME); Tay-Sachs disease/GM2 gangliosidosis; Christianson syndrome; Lowe oculocerebrorenal syndrome; Charcot-Marie-Tooth type 4J; CMT4J; Yunis-Varon syndrome; and/or X-linked hypercalciuric nephrolithiasis.

The mucopolysaccharidoses disorder may be selected from the group consisting of MPS I, Hurler syndrome; MPS I, Hurler-Scheie syndrome; MPS I, Scheie syndrome; and/or MPS II, Hunter syndrome. The neuronal ceroid lipofuscinosis may be selected from the group consisting of CLN6 disease—Atypical Late Infantile, Late-Onset variant, Early Juvenile, Batten-Spielmeyer-Vogt/Juvenile NCL/CLN3 disease, Finnish Variant Late Infantile CLN5, Jansky-Bielschowsky disease/Late infantile CLN2/TPP1 Disease, Kufs/Adult-onset NCL/CLN4 disease, Northern Epilepsy/variant late infantile CLN8, and/or Santavuori-Haltia/Infantile CLN1/PPT disease.

In view of the above, it is believed that inhibition of PIKfyve activity would be effective in treating lysosomal storage disorders. Consequently, the present invention provides methods of treating lysosomal storage disorders by administering therapeutically effective amounts of the PIKfyve-inhibiting compounds of the present invention.

d. Treating Filovirus Infections

Cell entry by EBOV is a complex process (Moller-Tank et al., PLoS Pathog. 2015; 11: e100473; White et al., Traffic. John Wiley & Sons A/S; 2016) entailing virus binding to cell surface attachment factors, internalization by macropinocytosis, processing by endosomal proteases, and transport to endolysosomes containing Niemann-Pick C1 (NPC1) (Cote et al. Nature. 2011; 477: 344-348; Carette et al., Nature. 2011; 477: 340-343), the intracellular receptor for EBOV (Miller et al., EMBO J. 2012; 31: 1947-1960). Finally, EBOV fuses with the limiting membrane of NPC1+ endolysosomes (Simmons et al., J Virol. American Society for Microbiology; 2015; 90: 605-610; Spence et al., MBio. American Society for Microbiology; 2016; 7: e01857-15; Mingo et al., J Virol. 2015; 89: 2931-2943) liberating its genome and associated proteins into the cytoplasm to begin replication. The essential role of NPC1 in EBOV entry and infection was powerfully illuminated in a haploid genetic screen (Carette et al., Nature. 2011; 477: 340-343). The same screen revealed other gene products critical for EBOV entry (Chandran et al., Science. 2005; 308: 1643-1645; Schomberg et al., J Virol. 2006; 80: 4174-4178) including many involved in endosome and lysosome biogenesis and maturation. One of the latter proteins was phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) (Carette et al., Nature. 2011; 477: 340-343), a lipid kinase that phosphorylates phosphatidylinositol-3-phosphate (PI3P) to generate phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2). PIKfyve and PI(3,5)P2 are known to be critical for endosome maturation (Elizabeth et al., PLoSNegl Trop Dis 11(4): e0005540).

PIKfyve inhibitor reportedly inhibits infection by both EBOV and MARV, being reported as notably effective in primary human macrophages, which are initial targets of filoviral infection (Dahlmann et al., Journal of Infectious Diseases. 2015; Martinez et al., J Virol. 2013; 87: 3801-3814). Mechanistic studies suggested that PIKfyve inhibitor blocks EBOV entry into the cell cytoplasm by working through PIKfyve and that its effect is to block viral particle trafficking to NPC1+ endolysosomes, the site of EBOV fusion (Simmons et al., J Virol. American Society for Microbiology; 2015; 90: 605-610; Spence et al., MBio. American Society for Microbiology; 2016; 7: e01857-15; Mingo et al., J Virol. 2015; 89: 2931-2943).

In view of the above, it is believed that inhibition of PIKfyve activity would be effective in treating filoviral entry and infection, and other complications associated with this condition. Consequently, the present invention provides methods of treating filoviruses, such as EBOV and MARV, and other complications associated with this condition, by administering therapeutically effective amounts of the PIKfyve-inhibiting compounds of the present invention alone or in a cocktail of small molecules to combat EVD.

e. Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)

The most common known cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is a hexanucleotide repeat expansion (HRE) in C9ORF72 that contributes to neurodegeneration by both loss-of-function (decreased C9ORF72 protein levels) and gain-of-function (e.g. dipeptide repeat protein production) mechanisms. Although therapeutics targeting the gain-of-function mechanisms are in clinical development, it is unclear if these will be efficacious given the contribution of C9ORF72 loss-of-function processes to neurodegeneration. Moreover, there is a lack of therapeutic strategies for C9ORF72 ALS/FTD with demonstrated efficacy in vivo. PIKFYVE is a Class-III Phosphatidylinositol-5-kinase (PI5K) that synthesizes PI(3,5)P2 from PI3P (Lemmon M A: Nat Rev Mol Cell Biol 2008, 9(2):99-111). PIKFYVE inhibition promotes endosomal maturation by increasing PI3P levels, and PI3P is also critical for autophagosome formation and engulfment of proteins designated for degradation (Martin S, et.al., PLoS One 2013, 8(3):e60152. Seebohm G, et.al., PLoS One 2012, 7(3):e33889). Therefore, PIKFYVE regulates cellular processes that are disrupted in C9-ALS/FTD, suggesting that altering PIKFYVE activity could modulate C9-ALS/FTD processes in patients.

In view of the above, it is believed that inhibition of PIKfyve activity would be effective in treating amyotrophic lateral sclerosis (ALS) and frontotemporal Dementia (FTD). Consequently, the present invention provides methods of treating ALS and FTD by administering therapeutically effective amounts of the PIKfyve-inhibiting compounds of the present invention

f. SARS-CoV-2

Phosphoinositides play many essential roles in endocytosis. Among them, one is phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2), which regulates early endosome to late endosome dynamics33,34. Phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is the main enzyme synthesizing PI(3,5)P2 in early endosome. Inhibition of PIKfyve by known PIKfyve inhibitors (Nat Commun 11, 1620 (2020)) significantly reduced entry of SARS-CoV S pseudovirions on 293/hACE2 cells in a dose dependent manner, whereas it had no effect on entry of VSV-G pseudovirions, which occurs in early endosomes. These results suggested that PIKfyve might be a potential general drug target for viruses that enter cells through endocytosis.

In view of the above, it is believed that inhibition of PIKfyve activity would be effective in treating SARS-CoV-2 entry. Consequently, the present invention provides methods of treating SARS-CoV-2 entry by administering therapeutically effective amounts of the PIKfyve-inhibiting compounds of the present invention

g. Neurodegeneration in Alzheimer's Disease

The key player in Alzheimer's disease, APP, interacts with the PIKfyve complex and regulates the PIKfyve pathway in C. elegans, establishing an entirely novel role for APP. The unexpected link between APP and endosomal phosphoinositide metabolism may suggest a novel and surprising mechanism for neurodegeneration in Alzheimer's disease (Balklava Z, et al. (2015), PLoS ONE 10(6): e0130485. doi:10.1371/journal.pone.0130485)

In view of the above, it is believed that modulation of PIKfyve activity would be effective in treating diseases associated with neurodegeneration in Alzheimer's disease. Consequently, the present invention provides methods of treating Alzheimer's disease by administering therapeutically effective amounts of the PIKfyve-inhibiting compounds of the present invention.

5. Methods of Making the Compounds of the Present Invention

Methods of making the compounds of the present invention, and intermediates used in their synthesis, are provided in the General Synthetic Schemes and Specific Syntheses Procedures below.

All reactions were performed in flame-dried or oven-dried glassware under a positive pressure of dry nitrogen or dry argon and were stirred magnetically unless otherwise indicated. All solvents and chemicals were purchased from standard commercial vendors and used as received unless otherwise noted. Any necessary preparations not referenced or described herein were facile and known to one of ordinary skill in the art. Yields are not optimized. The chemical names were generated using the BIOVIA DRAW™ 2017 R2 chemical drawing program, available from MDL INFORMATION SYSTEMS™, a division of SYMYX® TECHNOLOGIES, INC. (Santa Clara, Calif.).

Reactions were monitored by thin layer chromatography (TLC) using 0.25 mm silica gel 60 F254 plates purchased from EMD MILLIPORE™. Purification was performed with TELEDYNE ISCO™ COMBIFLASH® TLC retention factor (Rf). 1H nuclear magnetic resonance spectroscopy (NMR) spectra were recorded on a VARIAN MERCURY™ 400 MHz instrument. Proton chemical shifts are expressed in parts per million (ppm) relative to TMS and calibrated using residual undeuterated solvent as an internal reference. Mass spectra were recorded on AGILENT™ Q-TOF paired with an AGILENT™ 1290 INFINITY high performance liquid chromatography (HPLC) system. Compound purity was determined by an AGILENT™ HP1050 instrument with 4.6 mm×150 mm XTERRA® MS C18 3.5 μm column and UPCHURCH® 5 μm precolumn 24×12 mm. The flow rate was 1.2 mL/minute, and the injection volume was 5 μL. HPLC conditions were as follows: mobile phase A, HPLC grade water (0.1% trifluoroacetic acid (TFA)); mobile phase B, HPLC grade acetonitrile (0.1% TFA); UV detector, 250 nm; 95% A/5% B to 0% A/100% B in 10 minutes, 100% B in 10-11 minutes, 100% B to 95% A/5% B in 11-13 minutes, 95% A/5% B in 13-15 minutes.

ABBREVIATIONS AND ACRONYMS

When the following abbreviations are used herein, they have the following meaning:

-   Ac2O acetic anhydride -   anhy Anhydrous -   n-BuOH n-butanol -   t-BuOH t-butanol -   CD₃OD methanol-d4 -   Celite® diatomaceous earth filter agent, ® Celite Corp. -   CH₂Cl₂ methylene chloride -   DCM dichloromethane -   CI-MS chemical ionization mass spectroscopy -   conc concentrated -   dec decomposition -   bs broad singlet -   br broad -   DME dimethoxyethane -   DMF N,N-dimethylformamide -   DMSO dimethylsulfoxide -   DMSO-d₆ dimethylsulfoxide-d6 -   ELSD evaporative light scattering device -   EtOAc ethyl acetate -   EtOH ethanol (100%) -   Et₂O diethyl ether -   Et₃N triethylamine -   HPLC ESI-MS high performance liquid chromatography-electrospray mass     spectroscopy -   MPLC medium pressure liquid chromatography -   NMR nuclear magnetic resonance spectroscopy -   TOF-MS time-of-flight-mass spectroscopy -   NMM 4-methylmorpholine -   Ph₃P triphenylphosphine -   Pd(dppf)Cl₂     [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) -   Pd(PPh₃)₄ tetrakis(triphenylphosphine)palladium(0) -   Pd(OAc)₂ palladium(II) acetate -   P(O)Cl₃ phosphorous oxychloride -   Rf TLC retention factor -   Rt retention time (HPLC) -   rt room temperature -   THF tetrahydrofuran -   TFA trifluoroacetic acid -   TLC thin layer chromatography -   LC-MS (ESI) liquid chromatography-mass spectroscopy (electrospray     ionization) -   DIEA diisopropylethylamine -   MsCl methanesulfonylchloride -   AcOH acetic acid -   HCl hydrochloric acid -   H₂SO₄ sulfuric acid -   HNO₃ nitric acid -   HBr hydrobromic acid -   CDCl₃ chloroform-d3 -   CHCl₃ chloroform -   H₂O water -   NaOAc sodium acetate -   KOH potassium hydroxide -   NaOH sodium hydroxide -   NaCl sodium chloride -   NaHCO₃ sodium bicarbonate -   Na₂CO₃ sodium carbonate -   K₂CO₃ potassium carbonate -   Na₂SO₄ sodium sulfate -   MgSO₄ magnesium sulfate -   MeOH methanol -   SiO₂ silica gel -   K₃PO₄ potassium phosphate -   NH₄Cl ammonium chloride -   AIBN 2,2′-axo bisisobutyronitrile -   DMAP N,N-Dimethyl aminopyridine -   LG leaving group -   TsCl p-toluenesulfonyl chloride -   PG protecting group

Synthetic Schemes

The compound of the general formula 1a can be synthesized by known methods. 4-Chloro from compounds 1a can be replaced by a cyclic amine in organic solvent to provide 2a. The compound 2a is treated with R3NHL in organic solvents to provide compound 3a. The compound of the general formula 3a is further treated with acid in organic solvent to afford 4a. Verious substitutents were installed on the ring nitrogen to produce 5a.

The compounds of the general formula 1b can be synthesized by known methods. The compounds of general formulas 2b to 5b can be synthesized by similar general methods described for 2a to 5a.

The compound of the general formula 2c can be synthesized by known methods. The ester can be hydrolyzed to acid by treating with base or acid in organic solvents. The acid 3c can be converted to amide 4c under standard coupling conditions using various primary or secondary amines. The compound of the general formula 5c can be prepared by treating 4c with hydrazide in organic solvent. The compound of the general formula 5c can be further derivatized by treating with appropriately substituted aldehydes or ketones to produce 6c.

The ring B is selected from one of heterocyclic or carbocyclic aromatic compound described above. The compound of the general formula 1d is prepared by the known methods. One of the chloro from the compound of the general formula 1d is replaced with amine to produce 2d. The compound of the general formula 3d is prepared by reacting 2d R3-NH₂ and base in organic solvent. The compound of the general formula 4d can be prepared by reacting 2d with ring D under standard reaction conditions or substituted ring D is assembled using standard reaction conditions described within the scope of the invention.

General Synthetic Schemes

4-chloro is selectively displaced from compounds 1 with morpholine in organic solvent at 0-80° C. to provide 2. The hydrazine group was introduced by heating compound 2 with hydrazine hydrate or anhydrous hydrazine in dioxane. The hydrazine compounds 3 was reacted with various aldehydes or ketones in organic solvent with acid catalyst to provide compounds 4. The Boc protecting group can be removed by treating 4 with either 4M HCl in dioxane using EtOAc as solvent or TFA in DCM at rt to provide 5. The compounds of the general formula 6 can be prepared by reacting 5 with various acid chlorides or substituted isocyanates/isothiocyanates in organic solvent and appropriate base. The compound of the general formula 6 can also be prepared under standered coupling conditions using substituted acids and 5.

4-chloro is selectively displaced from compounds 7 with morpholine in MeOH or isopropanol to provide 8. The hydrazine group was introduced by treating compound 8 with hydrazine hydrate or anhydrous hydrazine in dioxane at 0° C.-80° C. The hydrazine compounds 9 is reacted with various aldehydes or ketones in organic solvent with acid catalyst to provide compounds 10. The Boc protecting group is removed by treating 10 with either 4M HCl in dioxane using EtOAc as a solvent or TFA in DCM at rt to provide 11. The compounds of the general formula 12 can be prepared by reacting 11 with various acid chlorides or substituted isocyanates/isothiocyanates in organic solvent and appropriate base. The compound of the general formula 12 can also be prepared under standered coupling conditions using substituted acids and 11.

The compound 13 was prepared by reacting 2 with R3-NH₂ in DMF and Cs2CO3 at 0-80° C. The protecting group in compound 13 was removed using standard acidic conditions followed further derivatization to produce 14. The compound 15 is prepared by reacting 3 with substituted ketoesters in organic solvents and/or in organic acids to provide 15 or 15a or a mixture of 15 and 15a. The boc protecting group is removed by treating 15 or 15a or a mixture of 15 and 15a with either 4M HCl in dioxane using EtOAc as solvent or TFA in DCM at rt followed by further derivatization to provide 16 or 16a or a mixture of 16 and 16a. Compound 17 is prepared by reacting 2 with various substituted pyrazole using standard conditions. Deprotection of boc followed further derivatization of 17 was carried out by a similar conditions described in scheme 2 to afford 18.

The compounds 20 to 24 were prepared using similar conditions described for scheme 3a using compound 8 with appropriate reagents.

The compound 26 was prepared by known methods. The compound 27 was prepared by reacting 26 with substituted ketoesters in organic solvents and/or in organic acids to provide 27 or 27a or a mixture of 27 and 27a.

The compound 28 was prepared by a known methods and ester group was hydrolysed to acid 29 by treating with 1N NaOH and methanol/THF. The acid was converted to amide using standard coupling reagents and various substituted amines to produce 30. The compound 30 was converted to corresponding hydrazide by treating with hydrazine hydrate in dioxane at 0-90° C. to afford 31. The hydrazine 31 was reacted with various aldehydes and ketones to produce 33. The compound 31 was reacted with various substituted ketoesters in organic solvents and/or in organic acids to afford 34 or 34a or mixture of 34 and 34a. The compound 32 is prepared by reacting 30 with substituted pyrazoles in organic solvents.

The ring B described above. The compound 36 can be prepared by reacting 35 with morpholine in ethanol at 0-80° C. The compound 37 can be prepared using ring D and 36 under standard Pd mediated coupling conditions or from 36, by similar reaction conditions described for compound 30 to 31, 31 to 34/34a and 30 to 32 in scheme 4a. The compound 38 can be prepared by reacting V-R3 and 36 in DMF and base. The compound 39 can prepared by similar conditions described in scheme 4a using 36.

SPECIFIC SYNTHESES Example 1 N-ethyl-4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide

Reagents & conditions: a) morpholine, DIEA, isopropanol, rt, 1 h; b) N2H4(98%), dioxane, reflux, 16 h; c) MeOH, m-tolualdehyde, CH₃CO₂H, 70° C., 16 h; d) 4M HCl in dioxane, EtOAc, rt, 16 h; e) ethyl isocyanate, DIEA, DCM, rt, 16 h.

Step 1: tert-butyl 2-chloro-4-morpholino-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate: To a suspension of tert-butyl 2,4-dichloro-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (0.500 g, 1.72 mmol) in isopropanol (8 mL) was added DIEA (0.600 mL, 3.44 mmol) at rt. To the above solution morpholine (0.180 mL, 2.06 mmol) was added drop wise at rt and the mixture was stirred further for 1 h at rt. At the end of this period solvent evaporated to dryness and to the residue DCM (50 mL) was added and washed with water (2×25 mL). The organic layer was dried (Na₂SO₄), filtered and the solvent evaporated to dryness to provide title compound (0.460 g, 79%). ¹H NMR (DMSO-d₆): δ 1.45 (s, 9H), 3.60-3.64 (m, 8H), 4.34 (bs, 2H), 4.68 (bs, 2H).

Step 2: tert-butyl 2-hydrazino-4-morpholino-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate: To suspension of tert-butyl 2-chloro-4-morpholino-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (0.310 g, 0.910 mmol) in dioxane (5 mL) was added Hydrazine (98%) (1 mL) at rt. The reaction mixture was refluxed for 16h. At the end of this period solvent and excess hydrazine was evaporated and the residue was co-evaporated with toluene (2×10 mL) to provide title product in quantitative yield. This product was used for the next step without further purification. ¹H NMR (DMSO-d₆): δ 1.42 (s, 9H), 3.54 (bs, 4H), 3.62 (bs, 4H), 4.18 (d, J=9.37 Hz, 2H), 4.52 (bs, 2H), 5.12 (bs, 2H), 7.62 (s, 1H). LC-MS: m/z 337.0 [M+H]⁺.

Step 3: tert-butyl 4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate: To a suspension of: tert-butyl 2-hydrazino-4-morpholino-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (0.160 g, 0.476 mmol) in methanol(5 mL) was added m-tolualdehyde (0.067 mL, 0.570 mmol) followed by 3 drops of AcOH. The mixture was heated at 70° C. for 6 h. The mixture was cooled to rt and the solid separated was collected and washed with methanol (4 mL) and dried to afford title product (0.100 g, 48%). ¹H NMR (DMSO-d₆): δ 1.40 (s, 9H), 3.62-3.65 (m, 8H), 4.30 (d, 13.6 Hz, 2H), 4.62 (bs, 2H), 7.14 (d, 7.12 hz, 1H), 7.31 (t, J=7.81 Hz, 1H), 7.42 (d, 2H), 8.02 (s, 1H), 10.92 (bs, 1H). LC-MS: m/z 439.0[M+H]⁺

Step 4: synthesis of 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine dihydrochloride: To suspension of tert-butyl 4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (1.00 g, 2.28 mmol) in EtOAc (20 mL) was added 4M HCl in dioxane (20 mL). The reaction mixture was stirred at rt for 16h. At the end of this period reaction mixture was evaporated to dryness to afford title product as hydrochloride salt in quantitative yield. ¹H NMR (DMSO-d₆): δ

Step 5: N-ethyl-4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide: To a suspension of 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine dihydrochloride (0.080 g, 0.194 mmol) in THF (5 mL) was added DIEA (0.067 mL, 0.188 mmol). To the above solution ethyl isocyanate (0.018 ml, 0.232 mmol) was added and stirring continued at rt for 14h. At the end of this period solvent was evaporated and the crude was chromatographed over SiO₂ using 0-20% gradient of MeOH in DCM to provide title product (0.044 g, 56%). LC-MS: m/z 410.0[M+H]⁺

Example 2 N-(4-Fluorophenyl)-4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide

The title product (0.062 g, 67%) was prepared by a similar procedure described for step 5 of example 1 using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine dihydrochloride (0.08 g, 0.194 mmol) and 4-fluorophenyl isocyanate(0.032 mL, 0.231 mmol). LC-MS: LC-MS: m/z 478.9[M+H]+

Example 3 4-Morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-N-(3-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide

The title product (0.047 g, 64%) was prepared by a similar procedure described for step 5 of example 1 using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine dihydrochloride (0.08 g, 0.194 mmol) and 3-pyridyl isocyanate(0.027 g, 0.231 mmol). ¹H NMR (DMSO-d₆): δ 2.31 (s, 3H), 3.67 (bs, 4H), 3.68 (bs, 4H), 4.48 (s, 2H), 4.80 (s, 2H), 7.13 (d, J=7.61 Hz, 1H), 7.25-7.30 (m, 2H), 7.39-7.41 (m, 2H), 7.95 (d, J=7.52 Hz, 1H), 8.01 (s, 1H), 8.16 (d, J=4.60 Hz, 1H), 8.56 (s, 1H), 8.71 (d, J=2.35 Hz, 1H), 10.83 (s, 1H).

Example 4 N-cyclopentyl-4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide

The title product (0.07 g, 80%) was prepared by a similar procedure described for step 5 of example 1 using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine dihydrochloride (0.08 g, 0.194 mmol) and cyclopentyl isocyanate(0.025, 0.231 mmol). H NMR (DMSO-d₆): δ 1.37-1.52 (m, 4H), 1.62-1.64 (m, 2H), 1.787-1.84 (m, 2H), 2.31 (s, 3H), 3.63-3.67 (m, 8H), 3.93-3.98 (m, 1H), 4.28 (s, 2H), 4.58 (s, 2H), 6.09 (d, 1H, J=7.20 Hz, 1H), 7.12 (d, J=7.81 Hz, 1H), 7.26 (t, J=7.61 Hz, 1H), 7.3807.40 (m, 2H), 8.01 (s, 1H), 10.77 (s, 1H). LC-MS: m/z 450.1 [M+H]⁺

Example 5 N-cyclobutyl-4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide

The title product (0.058 g, 68%) was prepared by a similar procedure described for step 5 of example 1 using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine dihydrochloride (0.08 g, 0.194 mmol) and cyclobutyl isocyanate(0.025, 0.231 mmol). ¹H NMR (DMSO-d₆): δ 1.15-1.60 (m, 2H), 1.92-1.98 (m, 2H), 2.10-2.17 (m, 2H), 2.31 (s, 3H), 3.63-3.68 (m, 8H), 4.12-4.18 (m, 1H), 4.27 (s, 2H), 4.58 (s, 2H), 6.50 (d, 7.72 Hz, 1H), 7.12 (d, J=7.61 Hz, 1H), 7.26 (t, J=7.4 Hz, 1H), 7.38 (s, 1H), 7.40 (s, 1H), 7.99 (s, 1H), 10.78 (s, 1H). LC-MS: m/z 436[M+H]⁺

Example 6 2-[(2E)-2-[(3-hydroxyphenyl)methylene]hydrazino]-4-morpholino-N-(3-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide

Step 1: 4-(2-chloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)morpholine hydrochloride: To a solution of tert-butyl 2-chloro-4-morpholino-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (1.2 g, 3.52 mmol) in EtOAc (30 mL) was added 4M HCl in dioxane (15 mL) at rt. The reaction mixture was stirred at rt for 16h, at the end of this period solvent was evaporated to dryness and the residue triturated with 10% EtOAc in hexanes to provide title product in quantitative yield. ¹H NMR (DMSO-d₆) δ3.60-3.64 (m, 8H), 4.20 (bs, 2H), 4.63 (bs, 2H), 9.00 (bs, 1H), 10.52 (bs, 2H).

Step 2: 2-chloro-4-morpholino-N-(3-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide: [025-125] To a suspension of 4-(2-chloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)morpholine hydrochloride (0.500 g, 1.60 mmol) in THF (20 mL) was added DIEA (1.11 mL, 6.38 mmol) and stirred for 5 min. To the above clear solution 3-isocyanatopyridine (0.23 g, 1.915 mmol) at rt and stirring continued for 16h at rt. The solid separated was collected and washed with EtOAc (2×5 mL) and dried under vacuum at 50° C. to afford title product (0.550 g, 96%). ¹H NMR (DMSO-d₆): δ 3.62 (bs, 8H), 4.44 (bs, 2H), 4.77 (bs, 2H), 7.15 (t, 1H), 7.85 (d, 1H), 8.05 (d, 1H), 8.52 (s, 2H), 9.07 (bs, 1H). LC-MS: m/z 361.0 [M+H]⁺

Step 3: 2-hydrazino-4-morpholino-N-(3-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide: To a suspension of 2-chloro-4-morpholino-N-(3-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide (0.400 g, 1.11 mmol) in dioxane (10 mL) was added hydrazine (98%)(1.00 mL) and the reaction mixture was refluxed for 16h. At the end of this period solvent was evaporated and residue was co-evaporated with toluene (2×15 mL) to provide title product in quantitative yield. This product was used for the next step without further purifications. LC-MS: m/z 357.0 [M+H]⁺

Step 4: 2-[(2E)-2-[(3-hydroxyphenyl)methylene]hydrazino]-4-morpholino-N-(3-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide: To a suspension of 2-hydrazino-4-morpholino-N-(3-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide (0.04 g, 0.112 mmol) in MeOH (3 mL) was added 3-hydroxybenzaldehyde (0.016 g, 0.134 mmol) and 3 drops of AcOH. The reaction mixture was refluxed for 5h. At the end of this period mixture was cooled to 40° C. and the solid separated was filtered and washed with MeOH (1 mL) and dried to afford title product (0.009 g, 17%). ¹H NMR (DMSO-d₆): δ 3.73 (bs, 8H), 4.59 (s, 2H), 4.86 (s, 2h), 6.79 (d, J=8.50 Hz, 1H), 7.13-7.23 (m, 4H), 7.36-7.39 (m, 1H), 8.01 (s, 1H), 8.05 (s 1H), 8.21 (d, 3.42 Hz, 1H), 8.77 (d, J=2.25 Hz, 1H), 8.81 (s, 1H), 9.59 (s, 1H). LC-MS: m/z 461.0 [M+H]⁺

Example 7 2-[(2E)-2-[(3-chlorophenyl)methylene]hydrazino]-4-morpholino-N-(3-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide

The title product (0.030 g, 38%) was prepared by a similar procedure described for step 4 of example 6 using 2-hydrazino-4-morpholino-N-(3-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide (0.06 g, 0.168 mmol) and 3-chloro benzaldehyde(0.028 g, 0.202 mmol). LC-MS: m/z 478.9 [M+H]⁺

Example 8 4-morpholino-N-(3-pyridyl)-2-[(2E)-2-[[3-(trifluoromethyl)phenyl]methylene]hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide

The title product (0.036 g, 42%) as prepared by a similar procedure described for step 4 of example 6 using 2-hydrazino-4-morpholino-N-(3-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide (0.06 g, 0.168 mmol) and 3-trifluoromethyl benzaldehyde (0.035 g, 0.202 mmol). LC-MS: m/z 513.3 [M+H]⁺

Example 9 2-[(2E)-2-[(3-methylsulfonylphenyl)methylene]hydrazino]-4-morpholino-N-(3-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide

The title product (0.041 g, 47%) was prepared by a similar procedure described for step 4 of example—using 2-hydrazino-4-morpholino-N-(3-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide (0.059 g, 0.165 mmol) and 3-methylsulfonylbenzaldehyde (0.036 g, 0.200 mmo). LC-MS: 522.90 [M+H]⁺

Example 10 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6-(3-pyridylmethyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-amine

To a solution of 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine dihydrochloride(0.120 g, 0.291 mmol) in DMF (4 mL) was added 3-(bromomethyl)pyridine hydrobromide (0.08 g, 0.350 mmol), K₂CO₃ (0.120 g, 0.873 mmol) and Bu₄NBr (20 mg). The reaction mixture was stirred at 60 for 16 h. At the end of this period water (20 mL) was added and extracted with EtOAc (2×30 mL). EtOAc layer was washed with water (2×15 mL), dried (Na2SO4), filtered and the solvet evaporated to dryness. The crude was purified by preparative TLC to afford title product (0.026 g). LC-MS: m/z 430.1 [M+H]⁺

Example 11 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6-(2-pyridylmethyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-amine

The title product (0.011 g) was prepared by similar procedure described for example 10 using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine dihydrochloride (0.120 g, 0.291 mmol) and 2-(chloromethyl)pyridine hydrochloride (0.057 g, 0.873 mmol). LC-MS: m/z 430.1[M+H]⁺

Example 12 [4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]-(4-pyridyl)methanone

To a solution of 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine (0.06 g, 0.177 mmol) in DCM was added isonicotinic acid (0.022 g, 0.177 mmol), TBTU (0.085 g, 0.265 mmol) and DIEA (0.123 mL, 0.71 mmol) at rt. The resulting mixture was stirred further at rt for 4h. At the end of this period solvent was evaporated to dryness and sat. NaHCO₃ solution (5 mL) was added. The solid separated was filtered, washed with water (2×5 mL) and dried under vacuum at 55° C. for 8h to provide title compound (0.058 g 74%). LC-MS: m/z 444.0 [M+H]⁺

Example 13 [4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]-(2-pyridyl)methanone

The title product (0.064 g, 82%) was prepared by a similar procedure described for example 12 using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine (0.06 g, 0.177 mmol), pyridine-2-carboxylic acid (0.022 g, 0.177 mmol), TBTU (0.085 g, 0.265 mmol) and DIEA (0.123 mL, 0.708 mmol). LC-MS: m/z 444 [M+H]⁺

Example 14 (5-methylisoxazol-4-yl)-[4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]methanone

The title product (0.038 g, 57%) was prepared by a similar procedure described for example 12, using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine (0.05 g, 0.147 mmol), 5-methylisoxazole-4-carboxylic acid (0.019 g, 0.154 mmol), TBTU (0.070 g, 0.220 mmol) and DIEA (0.051 mL, 0.294 mmol). LC-MS: m/z 448.4 [M+H]⁺

Example 15 6-(1-methylimidazol-4-yl)sulfonyl-4-morpholino-N-[(E)-m-tolylmethyleneamino]-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-amine

To a suspension of 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine (0.05 g, 0.148 mmol) was added DIEA (0.05 mL, 0.296 mmol). To the above mixture 1-methylimidazole-4-sulfonyl chloride (0.067 g, 0.177 mmol) was added and stirred for 30 min at rt. The solvent was evaporated to dryness, to the crude water (5 mL) was added and the solid separated was filtered and washed with water (5 mL) and dried to afford title product (0.069 g, 97%). ¹H NMR (DMSO-d₆): δ 2.30 (s, 3H), 3.56 (bs, 4H), 3.64 (bs, 4H), 3.67 (s, 3H), 4.32 (s, 2H), 4.70 (s, 2H), 7.12 (d, J=7.32 Hz, 1H), 7.25 (t, J=7.33 Hz, 1H), 7.37 (s, 1H), 7.39 (s, 1H), 7.78 (s, 1H), 7.90 (s, 1H), 7.98 (s, 1H), 10.81 (s, 1H).

Example 16 3-[[4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]sulfonyl]benzoic acid

Title compound (0.052 g, 34%) by a similar procedure described for example 15, using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine (0.100 g, 0.295 mmol), 3-chlorosulfonylbenzoic acid (0.078 g, 0.354 mmol) and DIEA (0.103 mL, 0.592 mmol). ¹HNMR (DMSO-d₆): δ 2.30 (s, 3H), 3.48-3.68 (m, 8H), 4.31 (s, 2H), 4.69 (s, 2H), 7.12 (d, 7.9 Hz, 1H), 7.25 (t, J=7.6 Hz, 1H), 7.36-7.38 (m, 2H), 7.98 (s, 1H), 8.16 (d, J=9.2 Hz, 1H), 8.20 (d, J=7.9 Hz, 1H), 8.33 (s, 1H), 10.80 (s, 1H).

Example 17 4-[[4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]sulfonyl]benzoic acid

Title compound (0.020 g, 26%) by a similar procedure described for example 15, using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine (0.050 g, 0.147 mmol), 4-chlorosulfonylbenzoic acid (0.039 g, 0.177 mmol) and DIEA (0.051 mL, 0.296 mmol). ¹HNMR (DMSO-d₆): δ 2.30 (s, 3H), 3.55-3.64 (m, 8H), 4.32 (s, 2H), 4.68 (s, 2H), 7.12 (d, J=7.5 Hz, 1H), 7.26 (t, J=7.6 Hz, 1H), 7.36 (d, 8.8 Hz, 1H), 7.38 (s, 1H), 7.97 (m, 3H), 8.11 (d, J=8.3 Hz, 2H), 10.79 (s, 1H).

Example 18 Exam6-[4-chloro-3-(trifluoromethyl)phenyl]sulfonyl-4-morpholino-N-[(E)-m-tolylmethyleneamino]-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-amine

Title compound (0.063 g, 73%) by a similar procedure described for example 15, using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine (0.050 g, 0.147 mmol), 4-chloro-3-(trifluoromethyl)benzenesulfonyl chloride (0.049 g, 0.177 mmol) and DIEA (0.051 mL, 0.296 mmol). ¹HNMR (DMSO-d₆): δ 2.30 (s, 3H), 3.50-3.73 (m, 8H), 4.38 (s, 2H), 4.72 (s, 2H), 7.12 (d, J=7.5 Hz, 1H), 7.26 (t, J=7.61 Hz, 1H), 7.36 (d, J=9.8 Hz, 1H), 7.39 (s, 1H), 7.97-7.99 (m, 2H), 8.17 (s, 1H), 8.23-8.26 (m, 2H), 10.80 (s, 1H).

Example 19 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6-(3-pyridylsulfonyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-amine

Title compound (0.032 g, 32%) by a similar procedure described for example 15, using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine (0.070 g, 0.207 mmol), pyridine-3-sulfonyl chloride (0.053 g, 0.248 mmol) and DIEA (0.108 mL, 0.621 mmol). ¹HNMR (DMSO-d₆): δ 2.34 (s, 3H), 3.56-3.70 (m, 8H), 4.60 (s, 2H), 4.79 (s, 2H), 7.20-7.40 (m, 2H), 7.64-7.72 (m, 3H), 8.19 (s, 1H), 8.34 (d, J=8.1 Hz, 1H), 8.89-9.10 (m, 1H), 9.10 (d, J=1.7 Hz, 1H), 12-46 (bs, 1H).

Example 20 6-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-morpholino-N-[(E)-m-tolylmethyleneamino]-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-amine

Title compound (0.110 g, 75%) by a similar procedure described for example 15, using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine (0.100 g, 0.295 mmol), 3,5-dimethyl-1H-pyrazole-4-sulfonyl chloride (0.060 g, 0.310 mmol) and DIEA (0.102 mL, 0.590 mmol). ¹HNMR (DMSO-d₆): δ 2.31 (s, 6H), 2.42 (s, 3H), 3.32 (bs, 4H), 3.64 (bs, 4H), 4.19 (s, 2H), 0.59 (s, 2H), 7.14 (d, J=7.9 Hz, 1H), 7.26 (t, J=7.2 Hz, 1H), 7.37-7.40 (m, 2H), 8.00 (s, 1H), 10.80 (s, 1H), 13.08 (s, 1H)

Example 21 N,N-dimethyl-4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-sulfonamide

Title compound (0.041 g, 75%) by a similar procedure described for example 15, using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine (0.100 g, 0.295 mmol), N,N-dimethylsulfamoyl chloride (0.034 mL, 0.325 mmol) and DIEA (0.102 mL, 0.590 mmol). ¹HNMR (DMSO-d₆): δ 2.32 (s, 3H), 3.55-3.80 (m, 8H), 7.17 (d, J=7.2 Hz, 1H), 7.29 (t, J=7.7 Hz, 1H), 7.46-7.48 (m, 2H), 8.06 (s, 1H), 11.26 (bs, 1H).

Example 22 6-(3,5-dimethylisoxazol-4-yl)sulfonyl-4-morpholino-N-[(E)-m-tolylmethyleneamino]-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-amine

Title compound (0.110 g, 75%) by a similar procedure described for example 15, using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine (0.100 g, 0.295 mmol), 3,5-dimethylisoxazole-4-sulfonyl chloride (0.060 g, 0.310 mmol) and DIEA (0.102 mL, 0.590 mmol). ¹H NMR (DMSO-d₆): δ 2.30 (s, 3H), 2.37 (s, 3H), 2.66 (s, 3H), 3.52-3.75 (m, 8H), 4.32 (s, 2H), 4.69 (s, 2H), 7.14-7.18 (m, 1H), 7.26 (t, J=7.4 Hz, 1H), 7.37-7.41 (m, 2H), 7.99 (s, 1H), 10.82 (s, 1H).

Example 23 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-amine

To solution of 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine dihydrochloride (0.08 g, 0.194 mmol) in DMF was added 2-chloropyrimidine(0.031 g, 0.272 mmol) and DIEA (0.135 mL, 0.776 mmol) at rt. The reaction mixture was heated at 120° C. for 1 h, cooled to rt and water was added and the solid separated was filtered and the filtered cake was washed with water. The crude was purified by preparative TLC to provide title product (0.019 g, 23%). ¹HNMR (DMSO-d₆): δ 2.31 (s, 3H), 3.69 (bs, 8H), 4.52 (s, 2H), 4.86 (s, 2H), 6.71 (t, J=4.70 Hz, 1H), 7.13 (d, J=7.50 Hz, 1H), 7.27 (t, J=7.90 Hz, 1H), 7.41 (d, J=6.93 Hz, 2H), 8.01 (s, 1H), 8.42 (d, J=4.69 Hz, 2H), 10.83 (s, 1H). LC-MS: m/z 417.0 [M+H]⁺

Example 24 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6-pyrimidin-4-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-amine

The title compound 0.025 g, 31%) was prepared by a similar procedure described for example 9, using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine dihydrochloride (0.08 g, 0.194 mmol), 4-chloropyrimidine 90.031 g, 0.272 mmol) and DIEA (0.135 mL, 0.776 mmol). LC-MS: m/z 417 [M+H]⁺

Example 25 4-[(3S)-3-methylmorpholin-4-yl]-N-[(E)-m-tolylmethyleneamino]-6-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-amine

Step 1: tert-butyl 2-chloro-4-[(3S)-3-methylmorpholin-4-yl]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate. The title product (0.480 g, 98%) was prepared by a procedure describe for step 1 of example 1 using tert-butyl 2,4-dichloro-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (0.400 g, 1.38 mmol), (3S)-3-methylmorpholine (0.166 g, 1.65 mmol) and DIEA (0.480 mL, 2.76 mmol). ¹H NMR (DMSO-d₆): δ 1.18 (d, J=6.64 Hz, 3H), 3.30 (bs, 2H), 3.42-3.45 (m, 1H), 3.54-3.59 (m, 1H), 3.65-3.69 (m, 1H), 3.87-3.90 (m, 2H), 4.32-4.35 (m, 2H), 4.62-4.76 (m, 2H).

Step 2: tert-butyl 2-hydrazino-4-[(3S)-3-methylmorpholin-4-yl]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate: the title product was prepared in quantitative yield by a similar procedure described for step 2 of example 1, using tert-butyl 2-chloro-4-[(3S)-3-methylmorpholin-4-yl]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (0.480 g, 1.35 mmol) and hydrazine (1.0 mL). The product was used for the next step without further purification.

Step 3: tert-butyl 4-[(3S)-3-methylmorpholin-4-yl]-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate: The title product (0.229 g, 71%) was prepared by a similar procedure described for step 3 of example 1 using tert-butyl 2-hydrazino-4-[(3S)-3-methylmorpholin-4-yl]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (0.250 g, 0.713 mmol) and m-tolualdehyde (0.100 mL, 0.852 mmol). ¹H NMR (DMSO-d₆): δ 1.30 (bs, 3H), 1.45 (s, 9H), 2.33 (s, 3H), 3.36-3.46 (m, 4H) 3.60-3.62 (m, 1H), 3.73-3.75 (m 1H), 3.94-3.96 (m 1H), 3.52-3.72 (m, 4H), 7.26 (d, J=8.0 Hz, 1H), 7.34 (t, J=7.3 Hz, 1H), 7.65 (bs, 2H), 8.19 (s, 1H).

Step 4: 4-[(3S)-3-methylmorpholin-4-yl]-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine: The title product was prepared in quantitative yield by a similar procedure described for step 4 of example 1 using tert-butyl 4-[(3S)-3-methylmorpholin-4-yl]-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (0.220 g, 0.486 mmol).

Step 5: 4-[(3S)-3-methylmorpholin-4-yl]-N-[(E)-m-tolylmethyleneamino]-6-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-amine: The title product(0.052 g, 47%) was prepared by a similar procedure describe for example 23 using 4-[(3S)-3-methylmorpholin-4-yl]-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine (0.100 g, 0.257 mmol), 2-chloropyrimidine (0.041 g, 0.360 mmol) and DIEA (0.370 mL, 2.106 mmol). LC-MS: m/z 431.0[M+H]⁺

Example 26 4-[(3R)-3-methylmorpholin-4-yl]-N-[(E)-m-tolylmethyleneamino]-6-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-amine

Step 1: tert-butyl 2-chloro-4-[(3R)-3-methylmorpholin-4-yl]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate: The title product (0.489 g, 100%) was prepared by a similar procedure described for step 1 of example 1 using tert-butyl 2,4-dichloro-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (0.400 g, 1.38 mmol), 3R)-3-methylmorpholine (0.166 g, 1.65 mmol) and DIEA (0.480 mL, 2.76 mmol). ¹H NMR (DMSO-d₆): δ 1.21 (d, J=6.7 Hz, 3H), 1.43 (s, 9H), 3.32 (bs, 2H), 3.40-3.45 (m, 1H), 3.54-3.59 (m, 1H), 3.66-3.69 (m, 1H), 3.88-3.90 (m, 2H), 4.30-4.40 (m, 2H), 4.6-4.80 (m, 2H).

Step 2: tert-butyl 2-hydrazino-4-[(3R)-3-methylmorpholin-4-yl]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate: the title product was prepared in quantitative yield by a similar procedure described for step 2 of example 1, using tert-butyl 2-chloro-4-[(3R)-3-methylmorpholin-4-yl]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (0.480 g, 1.35 mmol) and hydrazine (1.0 mL). The product was used for the next step without further purification.

Step 3: tert-butyl 4-[(3R)-3-methylmorpholin-4-yl]-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate: The title product (0.280 g, 87%) was prepared by a similar procedure described for step 3 of example 1 using tert-butyl 2-hydrazino-4-[(3R)-3-methylmorpholin-4-yl]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (0.250 g, 0.713 mmol) and m-tolualdehyde (0.100 mL, 0.852 mmol). ¹H NMR (DMSO-d₆): δ 1.29 (bs, 3H), 1.48 (s, 9H), 2.34 (s, 3H), 3.20-3.56 (m, 4H), 3.60-3.62 (m, 1H), 3.72-3.75 (m, 1H), 3.94-3.96 (m, 1H), 4.40-4.60 (m, 2H), 4.64-4.80 (m, 2H), 7.23-7.45 (m, 2H), 7.60-7.7.65 (m, 2H), 8.10 (s, 1H).

Step 4: 4-[(3R)-3-methylmorpholin-4-yl]-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine: The title product was prepared in quantitative yield using tert-butyl 4-[(3R)-3-methylmorpholin-4-yl]-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate (0.270 g, 0.596 mmol) in dioxane(10 mL) and 4M HCl in dioxane(5 mL).

Step 5: 4-[(3R)-3-methylmorpholin-4-yl]-N-[(E)-m-tolylmethyleneamino]-6-pyrimidin-2-yl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-amine: The title product(0.042 g, 38%) was prepared by a similar procedure describe for example 23 using 4-[(3R)-3-methylmorpholin-4-yl]-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine (0.100 g, 0.257 mmol), 2-chloropyrimidine (0.041 g, 0.360 mmol) and DIEA (0.370 mL, 2.106 mmol). LC-MS: m/z 431.0[M+H]⁺

Example 27 4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-N-(oxetan-3-yl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide

To a solution of oxetan-3-amine (0.250 g, 3.42 mmol) in acetonitrile (10 mL) was added CDI (0.665 g, 4.10 mmol) and the mixture was refluxed for 16h. The reaction mixture was cooled to rt and 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine hydrochloride(0.250 g, 0.607 mmol) was added followed by DIEA (0.317 mL, 1.08 mmol) at rt and acetonitrile (5 mL). The reaction mixture was refluxed for 3h. The solvent was evaporated and the crude was chromatographed over SiO2 using 0-15% MeOH in DCM to provide title product (0.120 g, 45%). ¹H NMR (DMSO-d₆): δ 2.31 (s, 3H), 3.31 (bs, 4H), 3.66 (bs, 4H), 4.32 (s, 2H), 4.51 (t, J=6.35 Hz, 2H), 4.63 (s, 2H), 4.69 (t, J=6.14 Hz, 2H), 4.75-4.79 (m, 1H), 7.05 (d, J=6.83, 1H), 7.13 (d, J=7.71 Hz, 1H), 7.27 (t, J=7.52, 1H) 7.04 (s, 1H), 7.42 (s, 1H), 8.01 (s, 1H), 10.90 (bs, 1H). LC-MS: 438.0 [M+H]⁺

Example 28 N-(azetidin-3-yl)-4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide

Step 1:tert-butyl 3-[[4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carbonyl]amino]azetidine-1-carboxylate: The title product (0.170 g, 77%) was prepared by a similar procedure described for example 27 using tert-butyl 3-aminoazetidine-1-carboxylate (0.150 g, 0.871 mmol), CDI (0.170 g, 1.04 mmol), 4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-amine hydrochloride (0.430 g, 1.04 mmol) and DIEA (0.550 mL, 3.12 mmol). LC-MS: m/z 537.0 [M+H]⁺.

Step 2: N-(azetidin-3-yl)-4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide: To a solution of tert-butyl 3-[[4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carbonyl]amino]azetidine-1-carboxylate (0.170 g, 0.316 mmol) in EtOAc (5 mL) was added 4M HCl in dioxane (3 mL) and the mixture was stirred at rt for 4h. The solvent was evaporated to dryness and the crude was chromatographed over SiO₂ using 0-20% MeOH in DCM to provide title product (0.023 g, 17%). LC-MS: m/z 437 [M+H]⁺

Example 29 7-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-amine

Step 1: tert-butyl 2-chloro-4-morpholino-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate: The title product (1.12 g, 97%) was prepared by a similar procedure described for step 1 of example 1 using tert-butyl 2,4-dichloro-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (1.00 g, 3.28 mmol), (0.166 g, 1.38 mmol), morpholine (0.350 g, 3.944 mmol) and DIEA (1.57 mL, 6.57 mmol). ¹H NMR (CDCl₃): δ 1.47 (s, 9H), 2.69 (t, J=5.6 Hz, 2H), 3.51 (t, J=6.7 Hz, 4H), 3.57 (t, J=5.6 Hz, 2H), 3.78 (t, J=6.6 Hz, 4H), 4.52 (s, 2H).

Step 2: tert-butyl 2-hydrazino-4-morpholino-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate: The title product was prepared in quantitative yield by a similar procedure described for step 2 of example 1, using tert-butyl 2-chloro-4-morpholino-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (1.12 g, 3.16 mmol) and hydrazine (0.92 mL, 18.93 mmol). The product was used for the next step without further purification.

Step 3: tert-butyl 4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate: The title product (0.490 g, 76%) was prepared by a similar procedure described for step 3 of example 1 using tert-butyl 2-hydrazino-4-morpholino-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (0.500 g, 1.43 mmol) and m-tolualdehyde (0.200 mL, 1.71 mmol). ¹H NMR (CDCl₃): δ 1.45 (s, 9H), 2.37 (s, 3H), 2.59 (bs, 2H), 3.43 (t, J=5.0 Hz, 4H), 3.55 (bs, 2H), 3.80 (t, J=5.1 Hz, 4H), 4.55 (s, 2H), 7.24 (d, J=6.8 Hz, 1H), 7.24 (t, J=6.9 Hz, 1H), 7.46 (d, J=7.5 Hz, 1H), 7.58 (s, 1H), 7.82 (s, 1H), 8.20 (s, 1H).

Step 4: 4-morpholino-N-[(E)-m-tolylmethyleneamino]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-aminedihydrochloride: The title product was prepared in quantitative yield using tert-butyl 4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (0.450 g, 9.94 mmol) in EtOAc (10 mL) and 4M HCl in dioxane (10 mL). ¹H NMR (DMSO-d₆): δ 2.34 (s, 3H), 2.87 (bs 2H) 3.23 (bs, 2H), 3.60-3.81 (m 8H), 4.33 (s, 2H), 7.26 (d, J=7.5 Hz, 1H), 7.34 (t, J=7.7 Hz, 1H), 7.69 (m, 2H), 8.24 (s, 1H), 10.20 (bs, 1H), 12.57 (bs, 1H).

Step 5: 7-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-morpholino-N-[(E)-m-tolylmethyleneamino]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-amine: Title compound (0.062 g, 67%) by a similar procedure described for example 15, using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-aminedihydrochloride (0.08 g, 0.188 mmol), 3,5-dimethyl-1H-pyrazole-4-sulfonyl chloride (0.040 g, 0.207 mmol) and DIEA (0.065 mL, 0.370 mmol). ¹H NMR (DMSO-d₆): δ 2.28 (s, 3H), 2.30 (s, 3H), 2.38 (s, 3H), 2.63 (bs, 2H), 3.20 (bs, 2H), 3.36 (bs, 4H), 3.66 (bs, 4H), 3.94 (s, 2H), (7.11 (d, J=7.3 Hz, 1H), 7.25 (t, J=7.7 Hz, 1H), 7.38 (bs, 2H), 8.00 (s, 1H), 10.82 (s, 1H), 13.11 (s, 1H).

Example 30 6-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-morpholino-N-[(E)-m-tolylmethyleneamino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-2-amine

Step 1: tert-butyl 2-chloro-4-morpholino-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate: The title product (1.16 g, 99%) was prepared by a similar procedure described for step 1 of example 1 using tert-butyl 2,4-dichloro-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate (1.00 g, 3.28 mmol), (0.166 g, 1.38 mmol), morpholine (0.350 g, 3.944 mmol) and DIEA (1.57 mL, 6.57 mmol). ¹H NMR (CDCl₃): δ 1.47 (s, (H), 2.88 (t, J=6.0 Hz, 2H), 3.46 (t, J=4.8 Hz, 4H), 3.69 (t, J=6.4 Hz, 2H), 3.79 (t, J=5.0 Hz, 4H), 4.39 (s, 2H).

Step 2: tert-butyl 2-hydrazino-4-morpholino-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate: The title product was prepared in quantitative yield by a similar procedure described for step 2 of example 1, using tert-butyl 2-chloro-4-morpholino-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate (1.12 g, 3.16 mmol) and hydrazine (0.92 mL, 18.93 mmol). The product was used for the next step without further purification.

Step 3: tert-butyl 4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate: The title product (0.47 g, 72%) was prepared by a similar procedure described for step 3 of example 1 using tert-butyl 2-hydrazino-4-morpholino-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate (0.500 g, 1.43 mmol) and m-tolualdehyde (0.200 mL, 1.71 mmol).

Step 4: 4-morpholino-N-[(E)-m-tolylmethyleneamino]-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-amine dihydrochloride: The title product was prepared in quantitative yield using tert-butyl 4-morpholino-2-[(2E)-2-(m-tolylmethylene)hydrazino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate (0.450 g, 9.94 mmol) in EtOAc (10 mL) and 4M HCl in dioxane (10 mL).

Step 5: 6-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-morpholino-N-[(E)-m-tolylmethyleneamino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-2-amine: Title compound (0.036 g), by a similar procedure described for example 15, using 4-morpholino-N-[(E)-m-tolylmethyleneamino]-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-amine dihydrochloride (0.08 g, 0.188 mmol), 3,5-dimethyl-1H-pyrazole-4-sulfonyl chloride (0.040 g, 0.207 mmol) and DIEA (0.065 mL, 0.370 mmol). ¹H NMR (DMSO-d₆): δ 2.31 (s, 9H), 2.76 (bs, 2H), 3.24 (bs, 4H), 3.68 (bs, 6H), 3.93 (s, 2H), 7.13 (bs, 1H), 7.26 (bs, 1H), 7.39 (s, 2H), 8.02 (s, 1H), 10.82 (s, 1H), 13.09 (s, 1H).

Example 31 and 32 5-methyl-1-[4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]pyrazole-3-carboxylic acid and 5-methyl-2-[4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]pyrazole-3-carboxylic acid

Step 1—ethyl 5-methyl-1-[4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]pyrazole-3-carboxylate and ethyl 5-methyl-2-[4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]pyrazole-3-carboxylate: To a solution of [4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]hydrazine (0.100 g, 0.304 mmol) in ACOH (3 mL) was added ethyl 2,4-dioxopentanoate (0.06 g, 0.36 mmol) at rt. The reaction mixture was heated at 120° C., 6h. At the end of this period mixture was cooled to rt and solvent evaporated and to the residue sat. NaHCO₃ solution was added and extracted with EtOAc (2×20 mL). The combined EtOAc layer was washed with water (25 mL) and brine (20 mL), EtOAc layer was dried (Na₂SO₄), filtered and solvent evaporated to dryness. The crude was chromatographed over SiO₂, using 5% MeOH in DCM to provide unseparable mixture of title compounds (0.110 g, 80%)

Step 2—5-methyl-1-[4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]pyrazole-3-carboxylic acid and 5-methyl-2-[4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]pyrazole-3-carboxylic acid: A mixture of ethyl 5-methyl-1-[4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]pyrazole-3-carboxylate and ethyl 5-methyl-2-[4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]pyrazole-3-carboxylate (0.100 g, 0.221 mmol) in THF:MeOH:H₂O (2:1:1) (16 mL) was added LiOH.H₂O (0.055 g 1.33 mmol). The mixture was stirred at rt for 15 h, at the end of this period solvent evaporated and the residue was treated with 1M citric acid. The solid separated was filtered and the solid cake was washed with water (2×20 mL) and dried to afford title products (0.076 g, 82%). LC-MS: Rt=6.40 min, m/z 423.2[M+H]⁺, LC-MS: Rt=6.87 min m/z 423.2 [M+H]⁺

Example 33 2-[4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]-5-(m-tolyl)pyrazol-3-ol methane sulfonate

Step 1: A mixture of [4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]hydrazine (0.300 g, 1.10 mmol) and methyl 3-(m-tolyl)-3-oxo-propanoate(0.230 g, 1.20 mmol) in a mixture of EtOH (10 mL) and AcOH (1 mL) was heated at 70° C. for 16 h. At the end of this period mixture was cooled to rt and solvent evaporated to dryness and the residue was triturated with sat. NaHCO₃ solution. The solid separated was collected and chromatographed over SiO₂ using 0 to 20% MeOH in CH₂Cl₂ to afford title product. LC-MS: m/z 471.0[M+H]⁺

Step: To a suspension of step 1 product (0.180 g, 0.382 mmol) in EtOH was added CH₃SO₃H (0.052, 0.803 mmol) dropwise at 70° C. and stirring continued further for 1 h. Then the mixture was cooled to rt and the solid separated was collected and washed with ether and dried at 50° C. under vacuum to afford title product (0.150 g, 69%). ¹H NMR (DMSO-d₆): 2.32 (s, 3H), 2.35 (s, 3H), 3.83 (bs, 4H), 4.07 (bs, 4H), 6.11 (s, 1H), 7.17 (d, J=7.4 Hz, 1H), 7.30 (t, 1H, J=7.7 Hz, 1H), 7.63 (s, 1H), 7.65 (s, 1H), 8.23 (d, J=5.8 Hz, 2H), 8.48 (s, 1H), 8.89 (d, J=6.0 Hz, 2H).

Example 34 5-(3-methoxyphenyl)-2-[4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]pyrazol-3-ol

Title compound was prepared by a similar procedure describe for step 1 of example 33 using [4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]hydrazine and methyl 3-(3-methoxyphenyl)-3-oxo-propanoate. ¹HNMR (DMSO-d₆): δ 3.80 (s, 3H), 3.83 (bs, 4H), 4.06 (bs, 4H), 6.15 (s, 1H), 6.93 (d, J=7.33 Hz, 1H), 7.31-7.45 (m, 3H), 8.12-8.18 (m, 2H), 8.42 (s, 1H), 8.82 (d, J=5.3 Hz, 1H).

Example 35 5-(3-isopropoxyphenyl)-2-[4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]pyrazol-3-ol

Title compound was prepared by a similar procedure describe for step 1 of example 33 using [4-morpholino-6-(4-pyridyl)thieno[3,2-d]pyrimidin-2-yl]hydrazine and methyl 3-(3-isopropoxyphenyl)-3-oxo-propanoate. ¹HNMR (DMSO-d₆): δ 1.27 (d, J=5.3 Hz, 6H), 3.83 (ba, 4H), 4.07) bs, 4H), 4.67 (m 1H), 6.16 (s, 1H), 6.91 (bs, 1H), 7.20-7.45 (m, 3H), 7.89 (bs, 2H), 8.32 (s, 1H), 8.73 (bs, 2H).

Example 36 tert-butyl 2-[5-hydroxy-3-(m-tolyl)pyrazol-1-yl]-4-morpholino-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate

The title product was prepared by a similar procedure described for step 1 of example 33 using tert-butyl 2-hydrazino-4-morpholino-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate and methyl 3-(m-tolyl)-3-oxo-propanoate. ¹HNMR (CDCl₃): δ2.39 (s, 3H), 3.81 (bs, 8H), 4.50-4.60 (m 2H), 4.70-4.80 (m, 2H), 5.94 (s, 1H), 7.15 (d, J=7.72, 1H), 7.29 (t, J=7.42, 1H), 7.65 (d, J=7.41 Hz, 1H), 7.73 (s, 1H).

Example 37 2-[6-(3,5-dimethylisoxazol-4-yl)sulfonyl-4-morpholino-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]-5-(m-tolyl)pyrazol-3-ol

Step 1: The title product (0.180, 77%) was prepared by treating tert-butyl 2-[5-hydroxy-3-(m-tolyl)pyrazol-1-yl]-4-morpholino-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate in EtOAc with 4M HCl in dioxane. The product was used for the next step without further purification.

Step 2: The title product was prepared (0.046 g) was prepared by similar procedure described for example 22. ¹HNMR (DMSO-d₆): 2.30 (s, 3H), 2.37 (s, 3H), 2.66 (s, 3H), 3.67 (bs(8H), 4.45 (s, 2H), 4.85 (s, 2H), 6.95 (s, 1H), 7.19 (d, J=7.′ Hz, 1H), 7.30 (t, J=7.6 Hz, 1H), 7.63 (d, J=7.3 Hz, 1H), 7.68 (s, 1H).

Example 38 2-[5-hydroxy-3-(m-tolyl)pyrazol-1-yl]-4-morpholino-N-(3-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide methane sulfonate

The title product (0.138 g) was prepared by similar procedure described for step 1 of example 33 using 2-hydrazino-4-morpholino-N-(3-pyridyl)-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxamide and methyl 3-(m-tolyl)-3-oxo-propanoate. This product was converted to methane sulfonate salt by procedure similar to described for step 2 of example 33. ¹HNMR (DMSO-d₆): δ1.88 (s, 3H), 2.33 (s, 3H), 3.75 (bs, 8H), 4.68 (bs, 2H), 4.98 (bs, 2H), 6.09 (s, 1H), 7.10-7.18 (m, 1H), 7.28 (t, J=7.6 Hz, 1H), 7.60-7.65 (m, 2H), 7.80-7.86 (m, 1H), 8.8.42-8.61 (m, 2H), 9.15 (s, 1H), 9.55 (bs, 1H).

Example 39 tert-butyl 2-[3-(4-fluorophenyl)-5-hydroxy-pyrazol-1-yl]-4-morpholino-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate

The product was prepared by similar procedure described for example 33 using tert-butyl 2-hydrazino-4-morpholino-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate and methyl 3-(4-fluorophenyl)-3-oxo-propanoate. ¹HNMR (DMSO-d₆): δ 1.44 (s, 9H), 3.71 (bs, 8H), 1.99 (m, 2H), 4.73 (bs, 2H), 6.11 (s, 1H), 7.24 (t, J=8.80 Hz, 2H), 7.85-7.88 (m, 2H).

Example 40 5-(4-fluorophenyl)-2-(4-morpholino-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)pyrazol-3-ol; hydrochloride

The title product was prepared by treating tert-butyl 2-[3-(4-fluorophenyl)-5-hydroxy-pyrazol-1-yl]-4-morpholino-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylate in EtOAc with 4M HCL in dioxane. ¹HNMR (DMSO-d₆): δ 3.71 (bs, 8H), 4.40 (bs, 2H), 4.70 (bs, 2H), 6.12 (s, 1H), 7.25 (t, J=8.89 Hz, 2H), 7.85-7.88 (m, 2H), 10.27 (bs, 1H).

Example 41 7-morpholino-5-[(2E)-2-(m-tolylmethylene)hydrazino]-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide

Step 1—ethyl 5-chloro-7-morpholino-pyrazolo[1,5-a]pyrimidine-2-carboxylate: To a solution of ethyl 5,7-dichloropyrazolo[1,5-a]pyrimidine-2-carboxylate (0.800 g. 3.08 mmol) in DMF (20 mL) was added Et₃N (1.28 mL, 9.22 mmol) and morpholine (0.82 mL, 3.22 mmol) at 0° C., the mixture was stirred at rt for 1.5 h. Water (50 mL) was added and stirred for 30 min at rt. The solid separated was collected and cake was washed with water (2×20 mL) and dried to afford title product (0.72 g, 75%). LC-MS: m/z 311[M+H]⁺

Step 2—5-chloro-7-morpholino-pyrazolo[1,5-a]pyrimidine-2-carboxylic acid: To a solution ethyl 5-chloro-7-morpholino-pyrazolo[1,5-a]pyrimidine-2-carboxylate (0.700 g, 2.25 mmol) in a mixture of THF:EtOH (20 mL, 1:1 v/v) was added 1N NaOH (10 mL) at rt and stirring continued for further 3h. At the end of this period solvent was evaporated and the residue was acidified using 1N citric acid and stirred for 20 min. The solid separated was collected and washed with water (2×30 mL) and dried to afford title product (0.62 g, 97%). LC-MS: m/z 383[M+H]⁺

Step 3—5-chloro-7-morpholino-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide: To a solution of 5-chloro-7-morpholino-pyrazolo[1,5-a]pyrimidine-2-carboxylic acid (0.200 g, 0.707 mmol) in DCM (15 mL) was added DIEA (0.492 mL, 2.82 mmol), oxetan-3-amine (0.062 g, 0.848 mmol) and HATU (0.40 g, 1.06 mmol) at rt and stirring continued further for 3h. At the end of this period reaction mixture was diluted with DCM (50 mL) and washed with 1M citric acid (20 mL) followed by sat NaHCO₃ (2×20 mL). The DCM layer was dried (Na₂SO₄), filtered and the solvent evaporated to dryness to afford title product (0.200 g, 84%). LC-MS: m/z 338[M+H]⁺

Step 4—5-hydrazino-7-morpholino-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide: To a suspension of 5-chloro-7-morpholino-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide (0.200 g, 0.592 mmol) in dioxane (15 mL) was added N2H4.H₂O (0.048 mL, 3.55 mmol) and the mixture was heated at 90° C. for 16h. At the end of this period solvent was evaporated to dryness and the residue was co-evaporated with toluene (2×20 mL) to give title product in quantitative yield. This product is used for the next step without further purification.

Step 5—7-morpholino-5-[(2E)-2-(m-tolylmethylene)hydrazino]-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide: To suspension of 5-hydrazino-7-morpholino-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide (0.100 g, 0.299 mmol) in MeOH (1.5 mL) was added 3-methylbenzaldehyde (0.044 g, 0.360 mmol) and drop of AcOH. The mixture was heated at 70° C. for 6h, colled to rt and the solid separated was filtered and washed with cold MeOH (1 mL) to afford title product. LC-MS: m/z 436.2[M+H]⁺

Example 42 N-(3,3-difluorocyclobutyl)-7-morpholino-5-[(2E)-2-(m-tolylmethylene)hydrazino]pyrazolo[1,5-a]pyrimidine-2-carboxamide

Step 1—5-chloro-N-(3,3-difluorocyclobutyl)-7-morpholino-pyrazolo[1,5-a]pyrimidine-2-carboxamide: The title compound was prepared by similar procedure described for step 1 of example 41 using 5-chloro-7-morpholino-pyrazolo[1,5-a]pyrimidine-2-carboxylic acid (0.200 g, 0.701 mmol), 3,3-difluorocyclobutanaminehydrochloride (0.122 g, 0.848 mmol), DIEA (0.49 mL, 2.82 mmol) and HATU (0.430 g, 1.06 mmol) in DCM (15 mL). LC-MS: m/z 372.1 [M+H]⁺

Step 2—N-(3,3-difluorocyclobutyl)-5-hydrazino-7-morpholino-pyrazolo[1,5-a]pyrimidine-2-carboxamide: The title compound 0.35 g, 100%) was prepared by a similar procedure described for step 2 of example 41 using 5-chloro-N-(3,3-difluorocyclobutyl)-7-morpholino-pyrazolo[1,5-a]pyrimidine-2-carboxamide(0.350 g, 0.941 mmol) and N2H4.H₂O (0.270 mL, 5.64 mmol). LC-MS: m/z 368.2[M+H]⁺

Step 3—N-(3,3-difluorocyclobutyl)-7-morpholino-5-[(2E)-2-(m-tolylmethylene)hydrazino]pyrazolo[1,5-a]pyrimidine-2-carboxamide: The title compound (0.140 g) was prepared by a similar procedure described for step 3 of example 41 using N-(3,3-difluorocyclobutyl)-5-hydrazino-7-morpholino-pyrazolo[1,5-a]pyrimidine-2-carboxamide (0.350 g, 0.395 mmol), (0.130 mL, 1.14 mmol) and 2 drop AcOH in methanol (5 ml). ¹HNMR (DMSO-d₆): δ 2.33 (s, 3H), 2.71-2.90 (m, 4H), 3.68 (bs, 4H), 3.85 (bs, 4H), 4.25-4.28 (m, 1H), 6.39 (bs, 2H), 7.17 (d, J=7.23 Hz, 1H), 7.30 (t, J=7.52 Hz, 1H), 7.46 (s, 1H), 7.51 (d, J=7.81 Hz, 1H), 8.01 (s, 1H), 8.59 (d, J=7.0 Hz, 1H), 11.32 (s, 1H). LC-MS: m/z 470.1[M+H]⁺

Example 43 5-(3-acetamidophenyl)-7-(morpholin-4-yl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide

Step 1: ethyl 7-chloro-5-(3-nitrophenyl)pyrazolo[1,5-a]pyrimidine-2-carboxylate: To a suspension of ethyl 5-(3-nitrophenyl)-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate(1.70 g, 5.18 mmol) and POCl₃ (15 mL) was refluxed for 2h. At the end of this period POCl₃ was evaporated and the dark brown mass was quenched with ice water and neutralized with solid NaHCO₃. The mixture was extracted with EtOAc, the organic layer was collected and washed with sat. solution of NaHCO₃ and brine. The EtOAc layer was dried (Na₂SO₄), filtered and the solvent evaporated to dryness to afford ethyl 7-chloro-5-(3-nitrophenyl)pyrazolo[1,5-a]pyrimidine-2-carboxylate (1.55 g, 87%). LC-MS: m/z 347.0[M+H]⁺

Step 2: ethyl 7-(morpholin-4-yl)-5-(3-nitrophenyl)pyrazolo[1,5-a]pyrimidine-2-carboxylate To solution of ethyl 7-chloro-5-(3-nitrophenyl)pyrazolo[1,5-a]pyrimidine-2-carboxylate (1.50 g, 4.47 mmol) in DMF (20 mL) was added morpholine (0.59 mL, 6.70 mmol) at rt and the mixture was stirred at rt further for 3h. At the end of this period water was added and the mixture was extracted with EtOAc. The EtOAc layer was washed with water, brine and the organic layer was dried over (Na₂SO₄), filtered and the solvent was evaporated. The crude was chromatographed over SiO₂ using 0-20% MeOH in DCM to afford ethyl 7-(morpholin-4-yl)-5-(3-nitrophenyl)pyrazolo[1,5-a]pyrimidine-2-carboxylate (1.30 g, 76%). LC-MS: m/z 398.1[M+H]⁺

Step 3: 7-(morpholin-4-yl)-5-(3-nitrophenyl)pyrazolo[1,5-a]pyrimidine-2-carboxylic acid: To a solution of ethyl 7-(morpholin-4-yl)-5-(3-nitrophenyl)pyrazolo[1,5-a]pyrimidine-2-carboxylate (1.30 g, 3.27 mmol) in THF:MeOH:H₂O (2:1:1) (24 mL) was added LiOH.H₂O (0.82 g, 19.63 mmol) and the mixture was stirred for 16h at rt. At the end of this period solvent was evaporated and the residue was neutralized with 1M citric acid. The solid separated was collected and dried to afford 7-(morpholin-4-yl)-5-(3-nitrophenyl)pyrazolo[1,5-a]pyrimidine-2-carboxylic acid (1.0 g, 83%). LC-MS: m/z 370.0[M+H]⁺

Step 4: 7-(morpholin-4-yl)-5-(3-nitrophenyl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide: To a solution of 7-(morpholin-4-yl)-5-(3-nitrophenyl)pyrazolo[1,5-a]pyrimidine-2-carboxylic acid (1.0 g, 2.70 mmol) in DMF (10 mL) was added oxetan-3-amine (0.24 g, 3.25 mmol), HATU (2.05 g, 5.40 mmol) followed by DIEA (0.94 mL, 5.40 mmol) at rt. Then the reaction mixture was stirred at rt for 16h. At the end of this period water was added and the solid separated was collected and dried to afford 7-(morpholin-4-yl)-5-(3-nitrophenyl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide (0.72 g, 63%). LC-MS: m/z 425.1 [M+H]⁺

Step 5: 5-(3-aminophenyl)-7-(morpholin-4-yl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide: To a solution of 7-(morpholin-4-yl)-5-(3-nitrophenyl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide (0.72 g, 1.69 mmol) in a mixture of MeOH (20 mL) and AcOH (5 mL) was added Zn powder (0.55 g, 8.45 mmol) portion wise and stirred for 1 h at rt. The mixture was filtered and the solvent was evaporated. The residue was neutralized with sat NaHCO₃ solution and extracted with EtOAc, the organic layer was washed with sat. NaHCO₃ solution and followed by brine. The EtOAc layer was dried (Na₂SO₄), filtered and the solvent was evaporated to afford 5-(3-aminophenyl)-7-(morpholin-4-yl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide (0.480 g, 72%) LC-MS: m/z 395.1[M+H]⁺

Step 6: 5-(3-acetamidophenyl)-7-(morpholin-4-yl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide: To a 5-(3-aminophenyl)-7-(morpholin-4-yl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide (0.100 g, 0.252 mmol) in DMF was added AcOH (0.028 mL, 0.504 mmol), HATU (0.191 g, 0.504 mmol) and DIEA (0.174 mL, 1.00 mmol) was added at rt and stirring continued further for 16h at rt. At the end of this period water was added and extracted with EtOAc and washed with water. The EtOAc layer was dried(Na₂SO₄), filtered and the solvent was evaporated to dryness. The crude was chromatographed over SiO₂ using 0-15% MeOH in DCM to afford 5-(3-acetamidophenyl)-7-(morpholin-4-yl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide (0.061 g, 67%). LC-MS: m/z 437.1[M+H]⁺

Example 44 7-(morpholin-4-yl)-N-(oxetan-3-yl)-5-{3-[(pyridine-3-carbonyl)amino]phenyl}pyrazolo[1,5-a]pyrimidine-2-carboxamide

The title compound (0.075 g, 59%) was prepared by a similar procedure described for step 6 of example 43 using 5-(3-aminophenyl)-7-(morpholin-4-yl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide (0.100 g, 0.252 mmol) and pyridine-3-carboxylic acid (0.037 g, 0.302 mmol), HATU (0.143 g, 0.37 mmol) and DIEA (0.090 mL, 0.75 mmol). LC-MS: m/z 500.1[M+H]⁺

Example 45 5-(3-benzamidophenyl)-7-(morpholin-4-yl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide

The title compound (0.067 g, 54%) was prepared by a similar procedure described for step 6 of example 43 using 5-(3-aminophenyl)-7-(morpholin-4-yl)-N-(oxetan-3-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide (0.100 g, 0.252 mmol) and benzoic acid (0.036 g, 0.302 mmol), HATU (0.143 g, 0.37 mmol) and DIEA (0.090 mL, 0.75 mmol). LC-MS: m/z 499.1[M+H]⁺

Example 46 (2S)-2-amino-1-[2-{(2E)-2-[(3-methylphenyl)methylidene]hydrazinyl}-4-(morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl]propan-1-one

Step 1: To a solution of 2-{(2E)-2-[(3-methylphenyl)methylidene]hydrazinyl}-4-(morpholin-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine dihydrochloride (0.25 g, 0.607 mmol) in DMF (5 mL) was added L-Boc alanine (0.160 g, 0.85 mmol), HATU (0.35 g, 0.91 mmol) and DIEA (0.350 mL, 2.00 mmol) was added at rt and stirring continued further for 16h. At the end of this period water was added and mixture extracted with EtOAc (35 mL×2). The organic layer was washed with sat. NaHCO₃ (20 mL) solution followed by brine (25 mL) and dried over Na₂SO₄, filtered and the solvent evaporated to dryness. The crude was chromatographed over SiO₂ using gradient of EtOAc in DCM to afford tert-butyl {(2S)-1-[2-{(2E)-2-[(3-methylphenyl)methylidene]hydrazinyl}-4-(morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl]-1-oxopropan-2-yl}carbamate (0.240 g, 77%). LC-MS: m/z 510.3 [M+H]⁺

Step 2: (2S)-2-amino-1-[2-{(2E)-2-[(3-methylphenyl)methylidene]hydrazinyl}-4-(morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl]propan-1-one: To a solution of tert-butyl {(2S)-1-[2-{(2E)-2-[(3-methylphenyl)methylidene]hydrazinyl}-4-(morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl]-1-oxopropan-2-yl}carbamate (0.240 g, 0.47 mmol) in EtOAc (10 mL) was added 4M HCl in dioxane (4 mL) and stirred at rt for 16h. At the end of this period reaction mixture was evaporated to dryness and the solid was triturated with sat. NaHCO₃ and the solid was filtered and washed with water. The crude product was chromatographed over SiO₂ using gradient of MeOH (5% NH₄OH solution) in DCM to afford title product (0.116 g, 60%). LC-MS: m/z 410.1[M+H]⁺.

Following intermediates were prepared by a similar procedure described for step 1 of example 46 using 2-{(2E)-2-[(3-methylphenyl)methylidene]hydrazinyl}-4-(morpholin-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine dihydrochloride and appropriate aminoacids

Ana- Interme- lytical diate Structure Name data 1

tert-Butyl {(2R)-1-[2-{(2E)-2-[(3- methylphenyl)methylidene] hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H- pyrrolo[3,4-d]pyrimidin-6-yl]-1- oxopropan-2-yl}carbamate LC-MS: m/z 510.1 [M + H]⁺ 2

tert-Butyl {1-[2-{(2E)-2-[(3- metylphenyl)methylidene] hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H- pyrrolo[3,4-d]pyrimidine-6- carbonyl]cyclobutyl}carbamate LC-MS: m/z 536.2 [M + H]⁺ 3

tert-Butyl {3-[2-{(2E)-2-[(3- methylphenyl)methylidene] hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H- pyrrolo[3,4-d]pyrimidine-6- carbonyl]oxetan-3-yl}carbamate LC-MS: m/z 538.6 [M + H]⁺ 4

tert-Butyl {(2S)-4-amino- 1-[2-{(2E)-2-[(3-methylphenyl) methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H- pyrrolo[3,4-d]pyrimidin-6-yl]-1,4- dioxobutan-2-yl}carbamate LC-MS: m/z 553.1 [M + H]⁺ 5

tert-Butyl {(2R)-4-amino- 1-[2-{(2E)-2-[(3-methylphenyl) methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H- pyrrolo[3,4-d]pyrimidin-6-yl]-1,4- dioxobutan-2-yl}carbamate LC-MS: m/z 553.1 [M + H]⁺

Examples 47-51

Following intermediates 1-5 were prepared by a similar procedure described for step 2 of example 46

Analytical Example Structure Name data 47

(2R)-2-Amino-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}- 4-(morpholin-4-yl-5,7-dihydro-6H- pyrrolo[3,4-d]pyrimidin-6-yl]propan- 1-one LC-MS: m/z 410.1 [M + H]⁺ 48

(1-Aminocyclobutyl)[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}- 4-(morpholin-4-yl)-5,7-dihydro-6H- pyrrolo[3,4-d]pyrimidin-6- yl]methanone LC-MS: m/z 436.1 [M + H]⁺ 49

(3-Aminooxetan-3-yl)[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}- 4-(morpholin-4-yl)-5,7-dihydro-6H- pyrrolo[3,4-d]pyrimidin-6- yl]methanone LC-MS: m/z 438.9 [M + H]⁺ 50

(3S)-3-Amino-4-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}- 4-(morpholin-4-yl)-5,7-dihydro-6H- pyrrolo[3,4-d]pyrimidin-6-yl]-4- oxobutanamide LC-MS: m/z 453.1 [M + H]⁺ 51

(3R)-3-Amino-4-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}- 4-(morpholin-4-yl)-5,7-dihydro-6H- pyrrolo[3,4-d]pyrimidin-6-yl]-4- oxobutanamide LC-MS: m/z 453.1 [M + H]⁺

Example 52 (2S)-2-Hydroxy-1-[2-{(2E)-2-[(3-methylphenyl)methylidene]hydrazinyl}-4-(morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl]propan-1-one

To a solution of 2-{(2E)-2-[(3-methylphenyl)methylidene]hydrazinyl}-4-(morpholin-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine dihydrochloride (0.125 g, 0.304 mmol) in DMF (5 mL) was added L-lactic acid (0.039 g, 0.0.43 mmol), HATU (0.180 g, 0.47 mmol) and DIEA (0.160 mL, 0.910 mmol) was added at rt and stirring continued further for 16 h. At the end of this period water was added and mixture extracted with EtOAc (35 mL×2). The organic layer was washed with sat. NaHCO₃ (20 mL) solution followed by brine (25 mL) and dried over Na₂SO₄, filtered and the solvent evaporated to dryness. The crude was chromatographed over SiO₂ using gradient of EtOAc in DCM to afford title product (0.08 g, 64%). LC-MS: 411.1[M+H]⁺

Example 53 (2R)-2-Hydroxy-1-[2-{(2E)-2-[(3-methylphenyl)methylidene]hydrazinyl}-4-(morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl]propan-1-one

Title product (0.065 g, 52%) was prepared by a similar procedure described for example 52 using 2-{(2E)-2-[(3-methylphenyl)methylidene]hydrazinyl}-4-(morpholin-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine dihydrochloride and D-lactic acid LC-MS: 411.1[M+H]⁺

List of Additional Compounds of the Present Invention

Example Structure Name 54

2-Amino-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]-2-(oxetan-3-yl)ethan-1-one 55

(2S)-2-Amino-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]-2-(oxetan-3-yl)ethan-1-one 56

(2R)-2-Amino-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]-2-(oxetan-3-yl)ethan-1-one 57

(2S)-2-Amino-3-methyl-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]butan-1-one 58

(2R)-2-Amino-3-methyl-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]butan-1-one 59

(2S)-2-Amino-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]butan-1-one 60

(2R)-2-Amino-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]butan-1-one 61

(2S)-2-Amino-4-methyl-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]pentan-1-one 62

(2R)-2-Amino-4-methyl-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]pentan-1-one 63

(2R)-2,6-Diamino-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]hexan-1-one 65

(2S)-2,6-Diamino-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]hexan-1-one 66

(1-Aminocyclopropyl)[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]methanone 67

2-Amino-2-methyl-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]propan-1-one 68

2-Hydroxy-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]ethan-1-one 69

(1-Hydroxycyclopropyl)[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]methanone 70

2-Hydroxy-2-methyl-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]propan-1-one 71

1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]prop-2-en-1-one 72

1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]prop-2-yn-1-one 73

1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]but-2-yn-1-one 74

3-Cyclopropyl-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]prop-2-yn-1-one 75

1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]pent-2-yn-1-one 76

4-Hydroxy-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]but-2-yn-1-one 77

4-Amino-1-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]but-2-yn-1-one 78

6-(Azetidin-3-yl)-2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-6,7-dihydro-5H-pyrrolo[3,4- d]pyrimidine 79

1-{3-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]azetidin-1-yl}prop-2-en-1- one 80

2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-6-[(3S)-pyrrolidin-3-yl]-6,7- dihydro-5H-pyrrolo[3,4-d]pyrimidine 81

1-{(3S)-3-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]pyrrolidin-1-yl}prop-2-en-1- one 82

2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-6-[(3R)-pyrrolidin-3-yl]-6,7- dihydro-5H-pyrrolo[3,4-d]pyrimidine 83

1-{(3R)-3-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]pyrrolidin-1-yl}prop-2-en-1- one 84

2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-6-[(3S)-piperidin-3-yl]-6,7- dihydro-5H-pyrrolo[3,4-d]pyrimidine 85

1-{(3S)-3-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]piperidin-1-yl}prop-2-en-1- one 86

2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-6-[(3R)-piperidin-3-yl]-6,7- dihydro-5H-pyrrolo[3,4-d]pyrimidine 87

1-{(3R)-3-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]piperidin-1-yl}prop-2-en-1- one 88

2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-6-(piperidin-4-yl)-6,7- dihydro-5H-pyrrolo[3,4-d]pyrimidine 89

1-{4-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]piperidin-1-yl}prop-2-en-1- one 90

2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-6-(1,2,3,6-tetrahydropyridin- 4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine 91

1-{4-[2-{(2E)-2-[(3- methylphenyl)methylidene]hydrazinyl}-4- (morpholin-4-yl)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl]-3,6-dihydropyridin-1(2H)- yl}prop-2-en-1-one

Biochemical and Biological Examples

Protocol Description

Kinase assays. For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 phage and incubated with shaking at 32° C. until lysis. The lysates were centrifuged and filtered to remove cell debris. The remaining kinases were produced in HEK-293 cells and subsequently tagged with DNA for qPCR detection. Streptavidin-coated magnetic beads were treated with biotinylated small molecule ligands for 30 minutes at room temperature to generate affinity resins for kinase assays. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific binding. Binding reactions were assembled by combining kinases, liganded affinity beads, and test compounds in 1× binding buffer (20% SeaBlock, 0.17×PBS, 0.05% Tween 20, 6 mM DTT). Test compounds were prepared as 111× stocks in 100% DMSO. Kds were determined using an 11-point 3-fold compound dilution series with three DMSO control points. All compounds for Kd measurements are distributed by acoustic transfer (non-contact dispensing) in 100% DMSO. The compounds were then diluted directly into the assays such that the final concentration of DMSO was 0.9%. All reactions performed in polypropylene 384-well plate. Each was a final volume of 0.02 ml. The assay plates were incubated at room temperature with shaking for 1 hour and the affinity beads were washed with wash buffer (1×PBS, 0.05% Tween 20). The beads were then re-suspended in elution buffer (1×PBS, 0.05% Tween 20, 0.5 μM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 minutes. The kinase concentration in the eluates was measured by qPCR.

Compound Handling

An 11-point 3-fold serial dilution of each test compound was prepared in 100% DMSO at 100× final test concentration and subsequently diluted to 1× in the assay (final DMSO concentration=1%). Most Kds were determined using a compound top concentration=30,000 nM. If the initial Kd determined was <0.5 nM (the lowest concentration tested), the measurement was repeated with a serial dilution starting at a lower top concentration. A Kd value reported as 40,000 nM indicates that the Kd was determined to be >30,000 nM.

The compounds in the Table 1 described below show PIKfyve inhibition, where “A” represents a Kd of less than or equal to 1 nM (“A”≤1 nM), “B” represents a Kd of greater than 1 nM to less than or equal to 5 nM (1 nM<“B”≤5 nM), “C” represents a Kd of greater than 5 nM to less than or equal to 10 nM (5 nM<“C”≤10 nM). “D” represents a Kd of greater than 10 nM to less than or equal to 60 nM (10 nM<“D”≤60 nM). “E” represents a Kd of greater than 60 nM to less than or equal to 100 nM (60 nM<“E”≤100 nM). “F” represents a Kd of greater than 100 nM to less than or equal to 2000 nM (100 nM<“F”≤2000 nM)

TABLE 1 PIKfyve Example # Kd (nM) 1 C 2 C 3 B 4 B 5 B 6 E 7 D 8 F 9 ND 10 B 11 D 12 ND 13 ND 14 ND 15 A 16 B 17 B 18 ND 19 B 20 A 21 B 22 B 23 B 24 B 25 B 26 C 27 B 28 C 29 C 30 ND 31 ND 32 ND 33 A 34 C 35 ND 36 ND 37 F 38 C 39 ND 40 ND 41 A 42 B ND = not determined

All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The mere mentioning of the publications and patent applications does not necessarily constitute an admission that they are prior art to the instant application.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be understood that certain changes and modifications may be practiced within the scope of the appended claims.

REFERENCES

-   Côté M, Misasi J, Ren T, Bruchez A, Lee K, Filone C M, et al. Small     molecule inhibitors reveal NiemannPick C1 is essential for Ebola     virus infection. Nature. 2011; 477: 344-348. -   Moller-Tank S, Maury W. Ebola virus entry: a curious and complex     series of events. PLoS Pathog. 2015; 11: e1004731. -   White J M, Whittaker G R. Fusion of Enveloped Viruses in Endosomes.     Traffic. John Wiley & Sons A/S; 2016. -   Carette J E, Raaben M, Wong A C, Herbert A S, Obemosterer G,     Mulherkar N, et al. Ebola virus entry requires the cholesterol     transporter Niemann-Pick C1. Nature. 2011; 477: 340-343. -   Miller E H, Obemosterer G, Raaben M, Herbert A S, Deffieu M S,     Krishnan A, et al. Ebola virus entry requires the host-programmed     recognition of an intracellular receptor. EMBO J. 2012; 31:     1947-1960. -   Simmons J A, D'Souza R S, Ruas M, Galione A, Casanova J E, White     J M. Ebola virus Glycoprotein Directs Fusion through NPC1+     Endolysosomes. J Virol. American Society for Microbiology; 2015; 90:     605-610. -   Mingo R M, Simmons J A, Shoemaker C J, Nelson E A, Schomberg K L,     D'Souza R S, et al. Ebola Virus and Severe Acute Respiratory     Syndrome Coronavirus Display Late Cell Entry Kinetics: Evidence that     Transport to NPC1+ Endolysosomes Is a Rate-Defining Step. J Virol.     2015; 89: 2931-2943. -   Chandran K, Sullivan N J, Felbor U, Whelan S P, Cunningham J M.     Endosomal proteolysis of the Ebola virus glycoprotein is necessary     for infection. Science. 2005; 308: 1643-1645. -   Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J.     Role of Endosomal Cathepsins in Entry Mediated by the Ebola Virus     Glycoprotein. J Virol. 2006; 80: 4174-4178. -   Elizabeth A. Nelson, Julie Dyall, Thomas Hoenen, Alyson B. Bames,     Huanying Zhou, Janie Y. Liang, Julia Michelotti, William H. Dewey,     Lisa Evans DeWald, Richard S. Bennett, Patrick J. Morris, Rajarshi     Guha, Carleen KlumppThomas, Crystal McKnight, Yu-Chi Chen, Xin Xu,     Amy Wang, Emma Hughes, Scott Martin, Craig Thomas, Peter B.     Jahrling, Lisa E. Hensley, Gene G. Olinger, Jr., Judith M. White.     PLoSNegl Trop Dis 11(4): e0005540. -   Dahlmann F, Biedenkopf N, Babler A, Jahnen-Dechent W, Karsten C B,     Gnirss K, et al. Analysis of Ebola Virus Entry Into Macrophages.     Journal of Infectious Diseases. 2015. -   Martinez O, Johnson J C, Honko A, Yen B, Shabman R S, Hensley L E,     et al. Ebola virus exploits a monocyte differentiation program to     promote its entry. J Virol. 2013; 87: 3801-3814. 

What is claimed is:
 1. A compound according to Formula I

and pharmaceutically acceptable salts and solvates thereof, wherein: n=1 or 2; R represents a hydrogen atom, aryl, heteroaryl, alkyl, heterocyclyl, carbocyclo, carbocycloalkyl, carbocycloalkenyl, carbocycloalkynyl, heterocyclylalkyl, heterocycloalkenyl, heterocycloalkynyl, arylalkyl, arylalkenyl, arylalkynyl heteroarylalkyl, heteroarylalkenyl, or heteroarylalkynyl, any of which may have one more or substituents; W represents a single bond, CH2, —(CH2)n-, S(O), S(O2), NRa, C(O), C(O)NRa, NRaC(O), S(O2)NRa, NRaS(O2), CRa═CRb, C═NRa, or NRa═CRb, —O(CH2)n-, NRa(CH2)n-, wherein n=0 or 1-5 and Ra and Rb are the same or independently represent a hydrogen atom, aryl, heteroaryl, alkyl, heterocyclyl, carbocyclo, carbocycloalkyl, carbocycloalkenyl, carbocycloalkynyl, heterocyclylalkyl, heterocycloalkenyl, heterocycloalkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, or heteroarylalkynyl, any of which may have one more or substituents; R1 and R2 are the same or different, and independently represent a hydrogen atom, hydroxyl group, aryl, heteroaryl, cycloalkyl, or heterocyclyl; R3 is selected from the group consisting of a hydrogen atom, an alkyl group which may have one or more substituents, an alkylsulfonyl group which may have one or more substituents, an acyl group which may have one or more substituents, an alkoxycarbonyl group which may have one or more substituents, a C-amido group which may have one or more substituents, an aliphatic ring which may have one or more substituents, an aryl group which may have one or more substituents, a heteroaryl group which may have one or more substituents, and an aliphatic ring with one or more heteroatoms and which may have one or more substituents; L is selected from the group consisting of a hydrogen atom and a group represented by the following general formulas:

where n=0 or 1-3; R^(a) R^(b), R^(c), R^(d), and R^(e) each independently represent a hydrogen atom, C1-C6 alkyl group, aryl, heteroaryl, cycloalkyl, or heterocyclyl group, any of which may have one or more substituents; or, R3 and L together form a 4 to 6 membered heterocyclic or heteroaryl ring, optionally substituted by one or more substituents, these substituents independently representing a hydrogen atom, C1-C6 alkyl group, aryl, heteroaryl, carbocyclo, or heterocyclyl group, any of which may have one or more substituents; and Ring A is a carbocycle, heterocycle, or heteroaryl, any of which may have one or more substituents.
 2. A compound according to Formula II

and pharmaceutically acceptable salts and solvates thereof; wherein R, R1, R2, R3, L, W and ring A are as defined in claim
 1. 3. A compound according to Formula III

and pharmaceutically acceptable salts and solvates thereof, wherein R, R, R2, R3, L, an Ring A are as defined in claim 1 and wherein X, X1, and Y are independently nitrogen or carbon.
 4. (canceled)
 5. (canceled)
 6. (canceled)
 7. (canceled)
 8. (canceled)
 9. (canceled)
 10. (canceled)
 11. (canceled)
 12. (canceled)
 13. (canceled)
 14. (canceled)
 15. (canceled)
 16. (canceled)
 17. (canceled)
 18. (canceled)
 19. A compound according to claim 1, wherein Ring A is an optionally substituted 5-6 membered saturated or partially unsaturated heterocyclic ring having one or two heteroatoms independently selected from the ErouD consisting of nitrogen, oxygen and sulfur.
 20. A compound according to claim 1, wherein Ring A is:

where Q represents N or CH and M is O, S, S(O), S(O2), or NRd, where Rd is a hydrogen atom, a hydroxyl group, an alkyl group which may have one or more substituents, or an acyl group.
 21. A compound according to claim 1, wherein Ring A is an unsubstituted morpholinyl or optionally substituted tetrahydropyranyl.
 22. A compound according to claim 1, wherein Ring A is selected from the group consisting of:


23. A compound according to claim 1, wherein Ring A is an optionally substituted 5-10 membered saturated or partially unsaturated bridged bicyclic heterocyclic ring having at least one nitrogen, at least one oxygen, and optionally 1-2 additional heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.
 24. A compound according to claim 23, wherein Ring A is a bridged, bicyclic morpholino group.
 25. A compound according to claim 23, wherein Ring A is selected from the group consisting of:


26. A compound of claim 1, comprising any one of Example Nos. 1-91.
 27. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
 28. A method of treating cancer; systemic or chronic inflammation; rheumatoid arthritis; diabetes; obesity; T-cell mediated autoimmune disease; diseases associated with over production of IL12/IL23; lysosomal storage disorders; filovirus infections; ischemia; neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, and frontotemporal dementia; viral infection including SARS-CoV-2; and other complications associated with the foregoing diseases and disorders, in a human patient; the methods comprising identifying a patient in need of such treatment and administering a therapeutically effective amount of a compound of claim
 1. 29. A method of delaying the onset, or reducing the severity of, one or more symptoms of cancer; systemic or chronic inflammation; rheumatoid arthritis; diabetes; obesity; T-cell mediated autoimmune disease; diseases associated with over production of IL12/IL23; lysosomal storage disorders; filovirus infections; ischemia; neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, and frontotemporal dementia; viral infection including SARS-CoV-2; and other complications associated with the foregoing diseases and disorders, in a human patient; comprising identifying a patient in need of such treatment and administering a therapeutically effective amount of a compound of claim
 1. 30. The method of claim 28, wherein the lysosomal storage disorder comprises cholesteryl ester storage disease, gangliosidosis, Neimann-Pick disease, and MPS disorders.
 31. A method of making a compound of claim 1, comprising following an appropriate synthetic scheme disclosed herein.
 32. (canceled)
 33. (canceled)
 34. (canceled)
 35. (canceled)
 36. (canceled)
 37. A method of inhibiting the activity of PIKfyve in human cells, comprising contacting said cells with a compound of claim
 1. 38. The method of claim 37, wherein said cells are within the body of a human patient.
 39. A method of treating cancer; systemic or chronic inflammation; rheumatoid arthritis; diabetes; obesity; T-cell mediated autoimmune disease; diseases associated with over production of IL12/IL23; lysosomal storage disorders; filovirus infections; ischemia; neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, and frontotemporal dementia; viral infection including SARS-CoV-2; and other complications associated with the foregoing diseases and disorders, in a human patient; the method comprising identifying a patient in need of such treatment and administering a therapeutically effective amount of a compound of claim 1 and a therapeutically effective amount of a second chemotherapeutic agent, wherein said second chemotherapeutic agent is not a compound of claim 1, but has been shown to interact synergistically with said compound of claim
 1. 